Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 2117. Отображено 100.
12-01-2012 дата публикации

Acetals as perfuming ingredients

Номер: US20120010114A1
Автор: Murielle Haldimann Sanchez, Philippe Dupau
Принадлежит: Individual

Acetal derivatives of 2,2,3,6-tetramethyl-1-cyclohexane/ene-carbaldehyde of formula (I): for use in the perfumery industry as well as the resulting compositions or articles containing one or more of these compounds. In formula (I), one dotted line indicates the presence of a carbon-carbon single or double bond and the other dotted line indicates the presence of a carbon-carbon single bond, R 1 represents a hydrogen atom or a methyl or ethyl group; and each R, taken alone, simultaneously or independently, represents a C 1-3 alkyl or alkenyl group, or the R groups, taken together, represent a C 2-6 hydrocarbon group optionally including an oxygen atom.

Подробнее
Номер записи: 1
27-09-2012 дата публикации

Aryloxyanilide imaging agents

Номер: US20120244073A1
Автор: Dennis O' Shea, Harry John Wadsworth
Принадлежит: Individual

The present invention provides a novel radiolabeled aryloxyalinine derivative suitable for in vivo imaging. In comparison to known aryloxyalinine derivative in vivo imaging agents, the in vivo imaging agent of the present invention has better properties for in vivo imaging. The in vivo imaging agent of the present invention demonstrates good selective binding to the peripheral benzodiazepine receptor (PBR), in combination with good brain uptake and in vivo kinetics following administration to a subject.

Подробнее
Номер записи: 2
11-07-2013 дата публикации

Esters of hexanoic acids as intermediates for the preparation of atorvastatin

Номер: US20130178636A1
Автор: Ben De Lange, Henricus Leonardus Marie Elsenberg, Henricus Wilhelmus Leonardus Marie Vaessen
Принадлежит: DSM Sinochem Pharmaceuticals Netherlands BV

The invention relates to compounds of general formula (3) wherein R 4 is allyl, 2-butyl, cyclohexyl, 3-methyl-2-butyl or 4-methyl-2-pentyl, a method for the preparation of compounds of general formula (3) and their use in the preparation of atorvastatin.

Подробнее
Номер записи: 3
01-08-2013 дата публикации

FILMS AND PARTICLES

Номер: US20130195954A1
Автор: Azouz Solomon, Colson Yolonda L., Grinstaff Mark W., Griset Aaron, Wolinsky Jesse
Принадлежит:

Described herein are compounds and processes that can be used to prepare polymer-based films, particles, gels and related compositions, and processes for delivery of agents, and other uses. 3. The oligomer or polymer of claim 1 , wherein Ris hydrogen or methyl.4. The oligomer or polymer of claim 1 , wherein Q is oxygen.5. A composition comprising the oligomer or polymer of .6. A polymeric film or particle comprising an oligomer or polymer of .7. A polymeric particle of claim 6 , comprising a microparticle or nanoparticle.8. A polymeric particle of claim 7 , wherein the particle has a diameter between about 2 nm and 1 micron.9. The polymeric particle of comprising a first volume at a first pH claim 7 , and a second volume at a second pH claim 7 , different from the from the first pH.10. The polymeric particle of claim 9 , wherein the second volume is 1× or more greater than the first volume when the second pH is lower than the first pH.11. The polymeric particle of claim 9 , wherein the second volume is 4× or more greater than the first volume when the second pH is lower than the first pH.12. The polymeric particle of claim 9 , wherein the second volume is 8× or more greater than the first volume when the second pH is lower than the first pH.13. The polymeric particle of claim 9 , wherein the second volume is greater than the first volume and the change in volume is sufficient that the particle when within a cell during the volume change ruptures the cell or a cellular compartment.14. The polymeric particle of claim 9 , wherein the second volume is greater than the first volume and the change in volume is sufficient to cause the particle to become lodged claim 9 , embedded claim 9 , or immobilized in an anatomic location claim 9 , such as a lymph node claim 9 , airway claim 9 , cavity claim 9 , capillary claim 9 , or other tissue.15. The polymeric film or particle of claim 6 , further comprising an agent.16. The polymeric film or particle of claim 15 , wherein the ...

Подробнее
Номер записи: 4
01-08-2013 дата публикации

Substituted 1,3-Dioxanes and There Uses

Номер: US20130197030A1
Автор: Alberts Peteris, Meyer Jean-Philippe, Prathama Mainkar S., Sorensen Alexandra Santana
Принадлежит: EVOLVA SA

The present invention relates to compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer. 35-. (canceled)719-. (canceled)20. A method for treating or preventing a disorder associated with a thromboxane A2 or peroxisome proliferator-activated receptors claim 1 , the method comprising: administering to a subject an effective amount of a compound of or acceptable salts claim 1 , N-oxides claim 1 , hydrates claim 1 , or solvates thereof; and a pharmaceutically-acceptable carrier or diluent.21. The method of claim 20 , wherein the disorder is cancer.2228-. (canceled)29. The method according to claim 20 , wherein said disorder is selected from the group consisting of myocardial infarction claim 20 , thrombosis claim 20 , thrombotic disorders claim 20 , pulmonary hypertension claim 20 , atherosclerosis claim 20 , diabetic nephropathy claim 20 , retinopathy claim 20 , peripheral arterial disease claim 20 , lower limb circulation claim 20 , pulmonary embolism claim 20 , thrombus formation claim 20 , stent-triggered thrombus formation claim 20 , stent-triggered hyperplasia hyperplasia claim 20 , septic shock claim 20 , preeclampsia claim 20 , asthma claim 20 , allergic rhinitis claim 20 , tumour angiogenesis and metastasis.3034-. (canceled)35. A pharmaceutical composition comprising the compound according to and a pharmaceutically acceptable carrier.3639-. (canceled) This application claims the benefit of and claims priority from U.S. provisional Application Ser. No. 60/989,805, filed Nov. 21, 2007, U.S. provisional Application Ser. No. 60/989,806, filed Nov. 21, 2007, U.S. provisional Application Ser. No. 60/989,808, filed Nov. 21, 2007, and PCT Application No. PCT/US07 ...

Подробнее
Номер записи: 5
22-08-2013 дата публикации

INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD

Номер: US20130217899A1
Автор: Marom Ehud, Mizhiritskii Michael, Rubnov Shai
Принадлежит: MAPI PHARMA LTD.

The present invention relates to processes for the preparation of (2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (Fingolimod) and pharmaceutically acceptable salts thereof, and intermediates formed in such processes. 142-. (canceled)44. The process according to claim 43 , wherein step (a) is conducted in the presence of a Friedel-Crafts catalyst claim 43 , a metal salt of an organic acid claim 43 , or a protic acid claim 43 , wherein{'sub': 3', '3', '4', '4', '2', '3, 'the Friedel Crafts catalyst is selected from AlCl, FeCl, SnCl, TiCl, ZnCland BF;'}the metal salt of an organic acid is a metal triflate selected from hafnium triflate and cerium triflate; and{'sub': 2', '4', '3', '3, 'the protic acid is selected from HF, HSO, CFSOH and an ion-exchange resin which is selected from Nafion or zeolite.'}45. The process according to claim 43 , wherein the reducing agent in step (b) is NaBH.46. The process according to claim 43 , wherein the hydroxy protecting group P in compound (13A) is acetyl (COCH) claim 43 , and wherein in step (c) the protection of 3-nitro-1-(4-octylphenyl)propan-1-ol is carried out by acylation with acetic anhydride or acetyl chloride in the presence of a base.47. The process according to claim 43 , whereinthe reduction of 3-nitro-1-(4-octylphenyl)propan-1-one (12) to 3-nitro-1-(4-octylphenyl)propan-1-ol and its conversion to compound (13A) is carried out in one step without isolation of intermediates; orwherein in step (d) the bis-hydroxymethylation of compound (13A) is carried out with formaldehyde or paraformaldehyde in the presence of a base; orwherein in step (d) the bis-hydroxymethylation of compound (13A) and deprotection to compound (14) is carried out in one step without isolation of intermediates.48. The process according to claim 43 , wherein the reduction step (e) comprises hydrogenating compound (14) to Fingolimod (1) in the presence of a Pd/C catalyst.50. The process according to claim 49 , wherein step (a) is ...

Подробнее
Номер записи: 6
12-09-2013 дата публикации

METHOD OF PREPARING CYCLIC CARBONATES, CYCLIC CARBAMATES, CYCLIC UREAS, CYCLIC THIOCARBONATES, CYCLIC THIOCARBAMATES, AND CYCLIC DITHIOCARBONATES

Номер: US20130237701A1
Автор: Hedrick James L., Nelson Alshakim, Sanders Daniel P.
Принадлежит: INTERNATIONAL BUSINESS MACHINES CORPORATION

A method of preparing a cyclic monomer, comprising: forming a first mixture comprising a precursor compound, bis(pentafluorophenyl)carbonate, and a catalyst; wherein the precursor compound has a structure comprising a) two or more carbons, and b) two functional groups selected from the group consisting of primary amine, secondary amine, thiol group, hydroxyl group, and combinations thereof; and agitating the first mixture at a temperature effective to form a second mixture comprising the cyclic monomer, the cyclic monomer selected from the group consisting of a cyclic carbonate, a cyclic carbamate, a cyclic urea, a cyclic thiocarbonate, a cyclic thiocarbamate, and a cyclic dithiocarbonate. 2. The method of claim 1 , wherein the bis(pentafluorophenyl)carbonate reacts only with the two X groups.3. The method of claim 1 , wherein each X group is OH.4. The method of claim 1 , wherein one X group is OH claim 1 , and another X group is NH.5. The method of claim 1 , wherein n is 1.6. The method of claim 1 , wherein the cyclic monomer is a cyclic carbonate.7. The method of claim 1 , wherein the cyclic monomer is a cyclic carbamate.8. The method of claim 1 , wherein the cyclic monomer is a cyclic urea.9. The method of claim 1 , wherein the cyclic monomer is a cyclic thiocarbonate.10. The method of claim 1 , wherein the cyclic monomer is a cyclic thiocarbamate.11. The method of claim 1 , wherein the cyclic monomer is a cyclic dithiocarbonate.12. The method of claim 1 , wherein the catalyst is cesium fluoride.14. The method of claim 13 , wherein each Y is O.15. The method of claim 13 , wherein one Y is O claim 13 , and another Y is NH.16. The method of claim 13 , wherein n is 1.18. The method of claim 17 , wherein each X is OH.19. The method of claim 17 , wherein one X is OH claim 17 , and another X is NH.20. The method of claim 17 , wherein the cyclic monomer is a cyclic carbonate.21. The method of claim 17 , wherein the cyclic monomer is a cyclic carbamate.22. The method of ...

Подробнее
Номер записи: 7
19-09-2013 дата публикации

Prodrugs of Fluorinated Mevalonates to Inhibit the Mevalonate Pathway of Streptococcus pneumoniae

Номер: US20130245284A1
Автор: Kang Soosung, Silverman Richard B., Watanabe Mizuki
Принадлежит:

Fluorinated prodrug compounds as can be used for selective streptococcal mevalonate pathway inhibition. 2. The compound of wherein X is selected from NH and O; and Ris selected from fluoromethyl and trifluoromethyl moieties.3. The compound of wherein Ris selected from mono- and polyfluoro-substituted arylalkyl moieties.4. The compound of wherein Ris selected from mono- and difluoro-substituted benzyl moieties.5. The compound of in at least one of human plasma and contact with an enzyme in a streptococcal mevalonate biosynthetic pathway.7. The compound of wherein X is selected from NH and O; and Ris selected from fluoromethyl and trifluoromethyl moieties.8. The compound of wherein Ris selected from aryl claim 7 , mono- and polyfluoroaryl claim 7 , arylalkyl claim 7 , mono- and polyfluoroarylalkyl moieties.9. The compound of wherein Ris selected from phenyl claim 8 , mono- and polyfluorophenyl claim 8 , benzyl claim 8 , monofluorobenzyl and polyfluorobenzyl moieties.11. The compound of wherein X is selected from NH and O; and Ris independently selected from fluoromethyl and trifluoromethyl moieties.12. The compound of where Ris selected from arylalkyl claim 11 , mono- and polyfluoro-substituted arylalkyl moieties.13. The compound of wherein Rand Rare independently selected from H and alkyl moieties.14. The compound of wherein at least one of Rand Ris methyl.16. The compound of wherein X is selected from NH and O; and Ris selected from fluoromethyl and trifluoromethyl moieties.17. The compound of wherein Ris selected from alkyl claim 16 , mono- and polyfluoro-substituted alkyl claim 16 , aryl claim 16 , mono- and polyfluoro-substituted aryl claim 16 , arylalkyl claim 16 , mono- and polyfluoro-substituted arylalkyl moieties.18. The compound of wherein X is O; Ris selected from alkyl claim 15 , aryl and arylalkyl moieties; and Rand Rare independently selected from H and acetyl moieties.19. The compound of wherein at least one of Rand Ris acetyl.21. The compound of ...

Подробнее
Номер записи: 8
26-09-2013 дата публикации

TANNIN INHIBITORS OF HIV

Номер: US20130252909A1
Автор: Kraus George A., Maury Wendy
Принадлежит: UNIVERSITY OF IOWA RESEARCH FOUNDATION

The invention provides a method to prevent or treat HIV-infection with synthetic tannins, and pharmaceutical compositions comprising synthetic tannins. 2. The method of wherein n is 1 claim 1 , m is 1 claim 1 , and p is 1.3. The method of wherein Ris CH.4. The method of wherein Rand Rare G or H.5. The method of wherein Ris G or H.6. The method of wherein Ris H or G and Ris H or G.7. The method of wherein Rand Rare H.8. The method of wherein Ris H.11. The method of wherein n is 0.13. The method of wherein Ror Ris CH.14. The method of wherein Rand/or Rare G.15. The method of wherein n is 1 claim 1 , m is 0 and p is 0.17. The method of wherein Rand/or Rare G.18. The method of wherein Ror Rare CH.20. The method of wherein Ris G.21. The method of wherein Rand Rare H.23. The method of wherein Rand/or Rare G.24. The method of wherein Ris H. This application claims priority of U.S. provisional patent application Ser. No. 61/614,792, filed Mar. 23, 2012, which is incorporated by reference herein.This invention was made with the support of the National Institutes of Health under Grant No. P50 AT004155. The U.S. Government has certain rights in the invention.With more than 33 million people currently infected with human immunodeficiency virus (HIV) and 2 million additional individuals infected each year, there is a worldwide imperative to reduce transmission of this deadly virus. Worldwide, sexual transmission is the primary route of new virus infections. Strategies to reduce spread of this virus can be achieved by reducing virus loads in currently infected individuals (and thereby reducing levels of virus exposure) and/or by blocking sexual transmission by the use of effective and safe microbicides.Clinically useful anti-retrovirals target a number of steps of the HIV-1 life cycle including co-receptor (CCR5) binding, virus membrane/cellular membrane fusion, reverse transcription, integration and proteolytic processing. See, e.g. Martins et al., 15, 1083 (2008). Combination ...

Подробнее
Номер записи: 9
26-09-2013 дата публикации

Prodrugs of Substituted 1,3-Dioxanes and Their Uses

Номер: US20130253045A1
Автор: Alberts Peteris, Sorensen Alexandra Santana
Принадлежит: EVOLVA SA

The present invention relates to prodrugs of compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The prodrugs of the compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer. 29-. (canceled)1115-. (canceled)16. A method for treating or preventing a disorder associated with a thromboxane A2 or peroxisome proliferator-activated receptors claim 1 , the method comprising: administering to a subject an effective amount of a compound of or acceptable salts claim 1 , N-oxides claim 1 , hydrates claim 1 , or solvates thereof; and pharmaceutically-acceptable carrier or diluent.17. The method of claim 16 , wherein the disorder is selected from the group consisting of diabetes claim 16 , cancer claim 16 , inflammation claim 16 , AIDS claim 16 , metabolic syndrome claim 16 , obesity claim 16 , pre-diabetes claim 16 , hypertension and dyslipidemia.18. The method of claim 17 , wherein the subject is a human.1923-. (canceled)24. The method of claim 16 , wherein the disorder is selected from the group consisting of myocardial infarction claim 16 , thrombosis claim 16 , thrombotic disorders claim 16 , pulmonary hypertension claim 16 , atherosclerosis claim 16 , diabetic nephropathy claim 16 , retinopathy claim 16 , peripheral arterial disease claim 16 , lower limb circulation claim 16 , pulmonary embolism claim 16 , thrombus formation claim 16 , stent-triggered thrombus formation claim 16 , stent-triggered hyperplasia claim 16 , septic shock claim 16 , preeclampsia claim 16 , asthma claim 16 , allergic rhinitis claim 16 , tumour angiogenesis and metastasis.25. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.26. (canceled)27. The composition according to claim 25 , wherein the ...

Подробнее
Номер записи: 10
03-10-2013 дата публикации

PHARMACEUTICAL AND FOOD COMPOSITIONS FOR PREVENTING OR TREATING DIABETES OR OBESITY

Номер: US20130261174A1
Автор: Han Se Jong, HARI DATTA Bhattarai, JO Dong-Gyu, Kang Pil-Sung, Kim Doc Kyu, Kim Il Chan, KIM Jung Eun, KIM Keun-Sik, Kim Sung Jin, Kim Tai Kyoung, LEE Cheolsoon, Lee Hyoung Seok, LEE Pyung Cheon, OH Hyun Cheol, Park Ha Ju, Park Heeyong, PARK Mi Ra, PARK Yu-Kyung, Yim Joung Han
Принадлежит: KOREA OCEAN RESEARCH AND DEVELOPMENT INSTITUTE

The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the . The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity. 926.-. (canceled) The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the Antarctic lichensAntarctic lichens are known to produce unique secondary metabolites different from those produced by higher plants (Ingolfsdottir, K., 61:729, 2002). The secondary metabolites produced by these lichens mostly belong to the chemical classes of depsides, depsidones, and dibenzofurans, and these compounds are supposed to be associated with the low growth rate of lichens (Kumar, K. C. S. et al., 62:817, 1999; Huneck, S., 86:559, 1999). In addition, the various biological activities of lichens, including antibiotic, antimycobacterial, antiviral, pain-killing, and antipyretic activities, and so on were found in screening processes (Ingolfsdottir, K., 61:729, 2002; Kumar, K. C. S. et al., 62:817, 1999). Thus, Interest has grown in the development of medical drugs using lichen metabolites.Meanwhile, diabetes is metabolic disorder symptom, including hyperglycemia, which results from defects in insulin action, insulin secretion, or both. Also, ...

Подробнее
Номер записи: 11
10-10-2013 дата публикации

Substituted 1,3-Dioxanes Useful as PPAR Modulators

Номер: US20130267561A1
Автор: Alberts Peteris, Bonnaud Thierry, Crameri Melya Hughes, Kelleher Joanne, Meyer Jean-Philippe, Pearson David, Prathama Mainkar S., Sorensen Alexandra Santana
Принадлежит: EVOLVA SA

Specifically useful stereoisomers of 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections as well as their use in the treatment of a disease related to TP, such as cardiovascular diseases. 25-. (canceled)720-. (canceled)21. The compound according to claim 1 , wherein said compound is (Z)-6-((2S claim 1 ,4S claim 1 ,5R)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1 claim 1 ,3-dioxan-5-yl)-hex-4-enoic acid.22. The compound according to claim 1 , wherein said compound is (Z)-6-((2S claim 1 ,4S claim 1 ,5R)-2-(2-chlorophenyl)-4-(2-methoxyphenyl)-1 claim 1 ,3-dioxan-5-yl)-hex-4-enoic acid.23. The compound according to claim 1 , wherein said compound is (Z)-6-((2S claim 1 ,4S claim 1 ,5R)-2-(2-chlorophenyl)-4-(2-acetoxyphenyl)-1 claim 1 ,3-dioxan-5-yl)-hex-4-enoic acid.24. The compound according to claim 1 , wherein said compound is methyl(Z)-6-((2S claim 1 ,4S claim 1 ,5R)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1 claim 1 ,3-dioxan-5-yl)hex-4-enoate.2549-. (canceled)50. A method of treating or preventing a clinical condition associated with TP in an individual in need thereof claim 6 , said method comprising a therapeutically effective amount of a compound of .51. The method according to claim 50 , wherein said clinical condition is selected from the group consisting of myocardial infarction claim 50 , thrombosis claim 50 , thrombotic disorders claim 50 , pulmonary hypertension claim 50 , atherosclerosis claim 50 , diabetic nephropathy claim 50 , retinopathy claim 50 , peripheral arterial disease claim 50 , lower limb circulation claim 50 , pulmonary embolism claim 50 , thrombus formation claim 50 , stent-triggered thrombus formation claim 50 , stent-triggered hyperplasia claim 50 , stent-induced restenosis claim 50 , hyperplasia claim 50 , septic shock claim 50 , preeclampsia claim 50 , asthma claim 50 , rhinitis claim 50 , ...

Подробнее
Номер записи: 12
07-11-2013 дата публикации

MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20130296373A1
Автор: Bravo-Altamirano Karla, Li Fangzheng, Meyer Kevin G., Nugent Benjamin M., Owen W. John, Renga James M., Wilmot Jeremy, Yao Chenglin
Принадлежит: DOW AGROSCIENCES LLC

The disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. The compound according to claim 1 , wherein X and Y are independently chosen from H or C(O)R.3. The compound according to claim 2 , wherein Ris independently chosen from H claim 2 , alkyl claim 2 , alkenyl claim 2 , aryl claim 2 , heterocyclyl claim 2 , silyl claim 2 , —C(O)R claim 2 , each substituted with 0 claim 2 , 1 or multiple R.4. The compound according to claim 3 , wherein Ris independently phenyl or cyclohexyl.5. The compound according to claim 4 , wherein Ris alkyl or aryl substituted with 0 claim 4 , 1 claim 4 , or multiple R.6. The compound according to claim 5 , wherein Ris alkoxy or benzyloxy substituted with 0 claim 5 , 1 claim 5 , or multiple R.7. The compound according to claim 6 , wherein Ris hydrogen or alkyl.8. The compound according to claim 1 , wherein X is H and Y is Q.10. The compound according to claim 9 , wherein Ris independently chosen from alkyl claim 9 , aryl claim 9 , or —C(O)R claim 9 , each substituted with 0 claim 9 , 1 or multiple R.11. The compound according to claim 10 , wherein Ris phenyl.12. The compound according to claim 11 , wherein Ris alkyl substituted with 0 claim 11 , 1 claim 11 , or multiple R.13. The compound according to claim 12 , wherein Ris alkyl claim 12 , aryl claim 12 , alkoxy claim 12 , or halo.14. A composition for the control of a fungal pathogen including at least one of the compounds according to and a phytologically acceptable carrier material.16Mycosphaerella graminicolaSeptoria triticiPuccinia triticinaPuccinia striiformisVenturia inaequalisUstilago maydisUncinula necatorRhynchosporium secalisMagnaporthe griseaPseudoperonospora cubensisPhakopsora pachyrhiziLeptosphaeria nodorumBlumeria graministriticiBlumeria graminishordeiErysiphe cichoracearumGlomerella lagenariumCercospora beticolaAlternaria solaniPyrenophora teres. The composition according to claim claim 1 , 14 wherein the plant pathogen is at least one ...

Подробнее
Номер записи: 13
07-11-2013 дата публикации

MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20130296375A1
Автор: Boebel Timothy A., Bravo-Altamirano Karla, Graupner Paul R., Heemstra Ronald J., Herrick Jessica, Li Fangzheng, Meyer Kevin G., Nugent Benjamin M., Owen W. John, Renga James M., Wang Nick X., Yao Chenglin
Принадлежит: DOW AGROSCIENCES LLC

The invention relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. A compound according to claim 1 , wherein:{'sub': '6', 'wherein, R is H, C(O)R;'}{'sub': 1', '6, 'Ris H, C(O)R;'}{'sub': 2', '5, 'Ris independently or separately H, alkyl, alkenyl, aryl, each substituted with 0, 1 or multiple R;'}{'sub': '3', 'Ris independently or separately H, methyl;'}{'sub': '5', 'Ris alkyl, alkoxy, halo, haloalkyl, or aryl; and'}{'sub': '6', 'Ris alkoxy, benzyloxy.'}5Mycosphaerella graminicolaSeptoria triticiPuccinia triticinaPuccinia striiformisVenturia inaequalisUstilago maydisUncinula necatorRhynchosporium secalisMagnaporthe griseaPseudoperonospora cubensisPhakopsora pachyrhiziLeptosphaeria nodorumBlumeria graministriticiBlumeria graminishordeiErysiphe cichoracearumGlomerella lagenariumCercospora beticolaAlternaria solaniPyrenophora teres. The compositions according to claim 4 , wherein the plant pathogen is least one pathogen selected from the group consisting of: Leaf Blotch of Wheat (; anamorph: ) claim 4 , Wheat Brown Rust () claim 4 , Stripe Rust () claim 4 , Scab of Apple () claim 4 , Blister Smut of Maize () claim 4 , Powdery Mildew of Grapevine () claim 4 , Barley scald () claim 4 , Blast of Rice () claim 4 , Downy Mildew of Cucurbits () claim 4 , Rust of Soybean () claim 4 , Glume Blotch of Wheat () claim 4 , Powdery Mildew of Wheat (f. sp. ) claim 4 , Powdery Mildew of Barley (f. sp. ) claim 4 , Powdery Mildew of Cucurbits () claim 4 , Anthracnose of Cucurbits () claim 4 , Leaf Spot of Beet () claim 4 , Early Blight of Tomato () claim 4 , and Net Blotch of Barley ().6Septoria triticiPuccinia triticinaPhakopsora pachyrhizi. The composition according to claim 5 , wherein the fungal pathogen is at least one of Leaf Blotch of Wheat () claim 5 , Wheat Brown Rust () claim 5 , and Rust of Soybean ().8. The method according to claim 7 , wherein the compound is applied in a mixture with at least one additional compound selected from the group ...

Подробнее
Номер записи: 14
23-01-2014 дата публикации

PREPARATION OF 3,5-DIOXO HEXANOATE ESTER IN TWO STEPS

Номер: US20140024842A1
Автор: Hu Guixian, Jackson Barry, Noti Christian
Принадлежит: LONZA LTD

The invention discloses a method for the preparation of tert-butyl 6-chloro-3,5-dioxohexanoate from Meldrum's acid derivative and its use for the preparation of tert-butyl(4R,65)-(6-hydroxymethyl-2,2-dimethyl-1,3-dioxan-4-yl)acetate (BHA), Rosuvastatin and Atorvastatin. 120-. (canceled)22. Method (B) according to claim 21 , wherein R1-IV and R3 are identical and are Cl or Br.23. Method (B) according to claim 21 , wherein base (B) is selected from the group consisting of N(R4)(R5)R6 claim 21 , 1 claim 21 ,4-diazabicyclo[2.2.2]octane claim 21 , a hexamethyldisilazide claim 21 , a Calkoxide salt of claim 21 , a Ccarboxylate salt of claim 21 , a carbonate salt of claim 21 , a hydrogen carbonate salt of claim 21 , a phosphate salt of claim 21 , a monohydrogenphosphate salt of or a dihydrogenphosphate salt of Na claim 21 , of K or of Li claim 21 , 1 claim 21 ,8-diazabicyclo[5.4.0]undec-7-ene claim 21 , NaNH claim 21 , KNH claim 21 , NaH claim 21 , KH claim 21 , CaH claim 21 , pyridine claim 21 , pyridine substituted with 1 or 2 independently selected identical or different Calkyl residues claim 21 , N claim 21 ,N-dimethyl-4-pyridinamine claim 21 , morpholine claim 21 , 4-methylmorpholine claim 21 , 1-methylpiperidine claim 21 , imidazol claim 21 , benzimidazol claim 21 , 2-methylimidazole claim 21 , 4-methylimidazole claim 21 , 2-ethylimidazole claim 21 , 2-ethyl-4-methylimidazole claim 21 , 2-isopropylimidazole claim 21 , 2-phenylimidazole claim 21 , 4-phenylimidazole claim 21 , picoline claim 21 , CsCO claim 21 , NaOH claim 21 , KOH claim 21 , Ca(OH)and mixtures thereof; with R4 claim 21 , R5 and R6 as defined in .24. Method (B) according to claim 21 , wherein R4 claim 21 , R5 claim 21 , R6 are identical or different and independently from each other selected from the group consisting of cyclohexyl claim 21 , phenyl claim 21 , methyl claim 21 , ethyl claim 21 , n-propyl claim 21 , iso-propyl claim 21 , n-butyl claim 21 , iso-butyl claim 21 , sec-butyl claim 21 , tert- ...

Подробнее
Номер записи: 15
13-02-2014 дата публикации

Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex

Номер: US20140045903A1
Автор: Carlson Glenn Richard, Chortyk Orestes, HORMANN Robert Eugene, Meyer Andrew, Opie Thomas R., Potter David W., Tice Colin M.
Принадлежит: Intrexon Corporation

The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. 114-. (canceled)15. A compound selected from the group consisting of:5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N′-(3,5-dimethyl-benzoyl)-N′-(1-ethyl-2,2-dimethyl-propyl)-hydrazide;5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N′-(3,5-dimethoxy-4-methyl-benzoyl)-N′-(1-ethyl-2,2-dimethyl-propyl)-hydrazide;5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N′-(1-tert-butyl-butyl)-N′-(3,5-dimethyl-benzoyl)-hydrazide;5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N′-(1-tert-butyl-butyl)-N′-(3,5-dimethoxy-4-methyl-benzoyl)-hydrazide;5-ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N′-(3,5-dimethyl-benzoyl)-N′-(1-ethyl-2,2-dimethyl-propyl)-hydrazide;5-ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N′-(3,5-dimethoxy-4-methyl-benzoyl)-N′-(1-ethyl-2,2-dimethyl-propyl)-hydrazide;5-ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N′-(1-tert-butyl-butyl)-N′-(3,5-dimethyl-benzoyl)-hydrazide;5-ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N′-(1-tert-butyl-butyl)-N′-(3,5-dimethoxy-4-methyl-benzoyl)-hydrazide;3,5-dimethoxy-4-methyl-benzoic acid N-(1-ethyl-2,2-dimethyl-propyl)-N′-(3-methoxy-2-methyl-benzoyl)-hydrazide;3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(3-methoxy-2-methyl-benzoyl)-hydrazide;3,5-dimethoxy-4-methyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(3-methoxy-2-methyl-benzoyl)-hydrazide;3,5- ...

Подробнее
Номер записи: 16
20-02-2014 дата публикации

INHIBITORS OF THE ACTIVITY OF COMPLEX III OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF FOR TREATING DISEASES

Номер: US20140051678A1
Автор: Clement-Schatlo Virginie, CRIBIU Riccardo, Fessard Thomas
Принадлежит: STEMERGIE BIOTECHNOLOGY SA

The present invention relates to compounds which are inhibitors of the activity of Complex III of the mitochondrial electron transport chain and pharmaceutical compositions comprising said compounds alone or in combination with other active agents. The present invention further relates to use of the compounds of the invention as medicaments or as agrochemicals where their properties as inhibitors of the mitochondrial respiration is of benefit. More particularly the present invention relates to the use of the compounds of the invention in a method of treating and/or preventing cancers presenting tumor-initiating cells. (Formula I) (I) 135.-. (canceled)37. The compound of claim 36 , wherein Ar is selected from (C5-C6)aromatic ring or (C5-C6)heteroaromatic ring where one or more of the carbon atoms in the ring system are replaced by heteroatoms selected from the group consisting of O claim 36 , S claim 36 , and N.38. The compound of claim 37 , wherein Ar is (C5-C6)aromatic ring.39. The compound of claim 36 , wherein A1 is —(C═O)—.40. The compound of claim 36 , wherein Aand Aare —C(═O)—.41. The compound of claim 36 , wherein Band Bare independently of each other selected from —O— claim 36 , —S— claim 36 , —NH— claim 36 , —CH— claim 36 , with the proviso that at least one of Band Bis not —O—.42. The compound of claim 36 , wherein Rand Rform together a (C3-C10)cycloalkyl or (C3-C10)heterocycloalkyl substituted by Rand R claim 36 , where Rand Rare independently of each other selected from —H claim 36 , —(C1-C10)alkyl claim 36 , —(C1-C10)alkenyl claim 36 , —(C1-C10)alkynyl claim 36 , mono or polyfluorinated (C1-C10)alkyl claim 36 , -aryl claim 36 , —OH claim 36 , —O—(C1-C10)alkyl claim 36 , —O—aryl claim 36 , —O(C═O)—(C1-C10)alkyl claim 36 , —O(C═O)-aryl claim 36 , and halogen.43. The compound of claim 36 , wherein R claim 36 , Rand Rare —H.44. The compound of claim 36 , wherein Rand Rform a bond together.45. The compound of claim 44 , wherein Aand Aare —C(═O)— and Ris H.46 ...

Подробнее
Номер записи: 17
20-02-2014 дата публикации

CONTINUOUS PROCESS FOR THE PRODUCTION OF BETA-KETO ESTERS BY CLAISEN CONDENSATION

Номер: US20140051869A1
Автор: Latham Elliot, McCormack Peter, Warr Antony John
Принадлежит: Phoenix Chemicals Limited

A continuous process for producing compounds having the general formula (6) is provided: 2. A process according to wherein the stoichiometric ratio of alkali metal or alkaline earth metal amide base claim 1 , alkyl lithium or a Grignard reagent to compound (5) supplied to the and/or to the separate reaction zone is less than about 4.5:1.3. A process according to wherein the steps of providing to the reaction zone a continuous stream of a compound of formula (3) and a continuous stream of an alkali metal or alkaline earth metal amide base claim 1 , alkyl lithium or Grignard reagent claim 1 , and the steps of providing to the or the separate reaction zone a continuous stream of a compound of formula (5) are sequential steps.4. A process according to wherein the temperature at which compounds (4) and (5) are reacted together is above 25° C.5. A process according to wherein the temperature at which compounds (4) and (5) are reacted together is above 30° C.6. A process according to wherein the residence time of the contacted continuous streams of compounds (4) and (5) in the or the separate reaction zone is less than about 5 minutes.7. A process according to wherein the residence time of the contacted continuous streams of compounds (4) and (5) in the or the separate reaction zone is less than about 1 minute.8. A process according to wherein the residence time of the contacted continuous streams of compounds (4) and (5) in the or the separate reaction zone is less than about 50 seconds.9. A process according to wherein the residence time of the contacted continuous streams of compounds (4) and (5) in the or the separate reaction zone is less than about 40 seconds.10. A process according to wherein the residence time of the contacted continuous streams of compound (3) and the alkali metal or alkaline earth metal amide base claim 1 , alkyl lithium or Grignard reagent in the reaction zone is less than about 5 minutes.11. A process according to wherein the enolate compound ...

Подробнее
Номер записи: 18
27-02-2014 дата публикации

2,2'-Binaphthalene Ester Chiral Dopants for Cholesteric Liquid Crystal Displays

Номер: US20140054498A1
Автор: Donald R. Diehl, Erica N. Montbach
Принадлежит: Kent Displays Inc, KENT STATE UNIVERSITY

A liquid crystal composition comprising a chiral dopant compound represented by the following structure (Structure 1): wherein: R1 and R2 are independently hydrogen, —(C═O)R9, —(C═O)R10, alkyl, aryl, alkaryl, alkenyl, cycloalkyl, alkoxyaryl, or heterocyclic all either substituted or unsubstituted, or combine to form a carbocyclic or heterocyclic ring; and R3-R9 are as described in the disclosure. Also featured are liquid crystal compositions comprising a chiral dopant compound represented by any of Structure 2-4 as described in the disclosure.

Подробнее
Номер записи: 19
20-03-2014 дата публикации

B- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS

Номер: US20140080902A1
Автор: Barroga Charlene F., Hood John, Kumar KC Sunil, Wallace David Mark
Принадлежит: Samumed, LLC

The present invention discloses β-diketones, γ-diketones or γ-hydroxyketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases. 1. (canceled)4. The method of claim 2 , wherein Ris a substituted or unsubstituted phenyl.12. The method of claim 10 , wherein Ris a substituted or unsubstituted phenyl.19. The method of claim 17 , wherein Ris a substituted or unsubstituted phenyl.27. The method of claim 25 , wherein Ris a substituted or unsubstituted phenyl.32. The method of claim 2 , wherein the compound is topically administered to the mammal.33. The method of claim 10 , wherein the compound is topically administered to the mammal.34. The method of claim 17 , wherein the compound is topically administered to the mammal.35. The method of claim 25 , wherein the compound is topically administered to the mammal. This application is a continuation application of U.S. application Ser. No. 13/211,665, filed Aug. 17, 2011, and claims the benefit of U.S. Provisional Application No. 61/427,974, filed Dec. 29, 2010, and U.S. Provisional Application No. 61/374,687, filed Aug. 18, 2010, each of which is incorporated herein by reference in its entirety.1. Field of the InventionThis invention relates to activators of one or ...

Подробнее
Номер записи: 20
20-03-2014 дата публикации

5-SEC-BUTYL-2-(2,4-DIMETHYL-CYCLOHEX-3-ENYL)-5-METHYL-[1,3]DIOXANE AND PROCESS FOR MAKING THE SAME

Номер: US20140081034A1
Автор: Gavalda Juan Adell, Narula Anubhav P.S., Perez Ana Maria Collado
Принадлежит: International Flavors & Fragrances Inc.

The present invention is directed to 5-sec-butyl-2-(2,4-dimethyl-cyclohex-3-enyl)-5-methyl-[1,3]dioxane and a novel process for making the same. 1. A process for preparing 5-sec-butyl-2-(2 ,4-dimethyl-cyclohex-3-enyl)-5-methyl-[1 ,3]dioxane consisting essentially of the steps of:(i) reacting 3-methyl-pent-3-en-2-one and hydrogen to provide 3-methyl-pentan-2-one;(ii) reacting 3-methyl-pentan-2-one of step (i) and methyl monochloroacetate to provide 3-sec-butyl-3-methyl-oxirane-2-carboxylic acid methyl ester;(iii) saponifying followed by acidifying and then decarboxylating 3-sec-butyl-3-methyl-oxirane-2-carboxylic acid methyl ester of step (ii) to provide 2,3-dimethyl-pentanal;(iv) reacting 2,3-dimethyl-pentanal of step (iii) and sodium hydroxide to provide 2-sec-butyl-2-methyl-propane-1,3-diol; and(v) reacting 2-sec-butyl-2-methyl-propane-1,3-diol of step (iv) and 2,4-dimethyl-cyclohex-3-enecarbaldehyde to provide 5-sec-butyl-2-(2,4-dimethyl-cyclohex-3-enyl)-5-methyl-[1,3]dioxane.2. The process of claim 1 , wherein step (i) is carried out at a temperature of about 85° C. and a pressure of about 10 bar.3. The process of claim 1 , wherein step (iii) decarboxylating is by refluxing at about 80-90° C.4. A process for preparing 5-sec-butyl-2-(2 claim 1 ,4-dimethyl-cyclohex-3-enyl)-5-methyl-[1 claim 1 ,3]dioxane consisting essentially of the steps of:(i) reacting 3-methyl-pent-3-en-2-one and hydrogen at a temperature of about 85° C. and a pressure of about 10 bar to provide 3-methyl-pentan-2-one;(ii) reacting 3-methyl-pentan-2-one of step (i) and methyl monochloroacetate to provide 3-sec-butyl-3-methyl-oxirane-2-carboxylic acid methyl ester;(iii) saponifying followed by acidifying and then decarboxylating 3-sec-butyl-3-methyl-oxirane-2-carboxylic acid methyl ester of step (ii) to provide 2,3-dimethyl-pentanal, wherein decarboxylating is by refluxing at about 80-90° C.;(iv) reacting 2,3-dimethyl-pentanal of step (iii) and sodium hydroxide to provide 2-sec-butyl-2-methyl- ...

Подробнее
Номер записи: 21
02-01-2020 дата публикации

METHOD FOR THE ONE-POT PRODUCTION OF ORGANO-IODINATED COMPOUNDS

Номер: US20200002269A1
Автор: PELLINGHELLI Stephan, PETTA Myriam
Принадлежит:

The present invention concerns a process for the preparation of organo-iodized compounds, as well as their preparation intermediates. More particularly, the present invention concerns a process for the preparation of organo-iodized compounds which can be used as preparation intermediates in the synthesis of iodized contrast agents. 19-. (canceled)11. The process of claim 10 , wherein the steps a) and b) are carried out in a single reactor.13. The process of claim 10 , wherein steps a) and b) are carried out in the presence of a solvent selected from the group consisting of dimethylacetamide claim 10 , propylene carbonate claim 10 , acetonitrile claim 10 , tetrahydrofuran claim 10 , and mixtures thereof.14. The process of claim 10 , wherein step b) is carried out in the presence of a chlorination agent selected from the group consisting of thionyl chloride claim 10 , phosphorus oxychloride claim 10 , phosphorus trichloride claim 10 , oxalyl chloride claim 10 , phosphorus pentachloride claim 10 , and methanoyl dichloride. The present invention relates to a process for the preparation of organo-iodized compounds, as well as their preparation intermediates. More precisely, the present invention relates to a process for the preparation of organo-iodized compounds used as preparation intermediates in the synthesis of iodized contrast agents.Currently, the majority of processes for the synthesis of iodized contrast agents use the dichloride of 5-amino-2,4,6-triiodoisophthalic acid (also known as DiCOCl), with the following formula:This compound is used in particular as an intermediate product in the synthesis of many contrast agents such as iopamidol (Iopamiron®), iohexol (Omnipaque®), ioversol (Optiray®), iomeprol (Iomeron®) or iobitridol (Xenetix®).During the synthesis of iodized contrast agents, it is necessary to carry out lengthy steps for separation and purification in order to obtain synthesis intermediates with a good level of purity. These steps considerably ...

Подробнее
Номер записи: 22
04-01-2018 дата публикации

MACROCYCLIC PICOLINAMIDE COMPOUNDS WITH FUNGICIDAL ACTIVITY

Номер: US20180002319A1
Автор: ARNOLD Amela, Bravo-Altamirano Karla, Daeuble, DeLorbe Johnathan E., Herrick Jessica, Jones David M., LaLonde Rebecca Lyn K.C., Li Fangzheng, Meyer Kevin G., Renga James M., SR. John F., Wilmot Jeremy, Yao Chenglin
Принадлежит:

This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. The compound according to claim 1 , wherein X and Y are hydrogen.3. The compound according to claim 2 , wherein Ris selected from the group consisting of hydrogen claim 2 , alkyl claim 2 , alkenyl claim 2 , and aryl claim 2 , each optionally substituted with 0 claim 2 , 1 claim 2 , or multiple R.4. (canceled)5. The compound according to claim 2 , wherein Ris independently selected for Rand Rfrom the group consisting of hydrogen claim 2 , alkyl claim 2 , alkenyl claim 2 , and aryl claim 2 , each optionally substituted with 0 claim 2 , 1 claim 2 , or multiple R.6. The compound according to claim 1 , wherein X is C(O)Rand Y is hydrogen.7. The compound according to claim 6 , wherein Ris selected from the group consisting of hydrogen claim 6 , alkyl claim 6 , alkenyl claim 6 , and aryl claim 6 , each optionally substituted with 0 claim 6 , 1 claim 6 , or multiple R.8. (canceled)9. The compound according to claim 6 , wherein Ris independently selected for Rand Rfrom the group consisting of hydrogen claim 6 , alkyl claim 6 , alkenyl claim 6 , and aryl claim 6 , each optionally substituted with 0 claim 6 , 1 claim 6 , or multiple R.10. The compound according to claim 1 , wherein X is hydrogen and Y is Q.11. The compound according to claim 10 , wherein Ris alkoxy.12. The compound according to claim 11 , wherein Ris hydrogen.13. The compound according to claim 12 , wherein Ris selected from the group consisting of hydrogen claim 12 , alkyl claim 12 , alkenyl claim 12 , and aryl claim 12 , each optionally substituted with 0 claim 12 , 1 claim 12 , or multiple R.14. (canceled)15. The compound according to claim 12 , wherein Ris independently selected for Rand Rfrom the group consisting of hydrogen claim 12 , alkyl claim 12 , alkenyl claim 12 , and aryl claim 12 , each optionally substituted with 0 claim 12 , 1 claim 12 , or multiple R.16. The compound according to claim 11 , ...

Подробнее
Номер записи: 23
04-01-2018 дата публикации

USE OF MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20180002320A1
Автор: ARNOLD Amela, Bravo-Altamirano Karla, Daeuble, DeLorbe Johnathan E., Herrick Jessica, Jones David M., LaLonde Rebecca Lyn K.C., Li Fangzheng, Meyer Kevin G., Renga James M., SR. John F., Wilmot Jeremy, Yao Chenglin
Принадлежит:

This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. A composition according to claim 1 , wherein X is hydrogen and Y is Q.3. A composition according to claim 2 , wherein Ris alkoxy.4. A composition according to claim 3 , wherein Ris hydrogen.5. A composition according to claim 4 , wherein Ris selected from the group consisting of hydrogen claim 4 , alkyl claim 4 , alkenyl claim 4 , and aryl claim 4 , each optionally substituted with 0 claim 4 , 1 claim 4 , or multiple R.6. (canceled)7. A composition according to claim 4 , wherein Ris independently selected for Rand Rfrom the group consisting of hydrogen claim 4 , alkyl claim 4 , alkenyl claim 4 , and aryl claim 4 , each optionally substituted with 0 claim 4 , 1 claim 4 , or multiple R.8. A composition according to claim 3 , wherein Ris selected from the group consisting of —C(O)Rand —CHOC(O)R.9. A composition according to claim 8 , wherein Ris alkyl claim 8 , optionally substituted with 0 claim 8 , 1 claim 8 , or multiple R.10. A composition according to claim 9 , wherein Ris selected from the group consisting of hydrogen claim 9 , alkyl claim 9 , alkenyl claim 9 , and aryl claim 9 , each optionally substituted with 0 claim 9 , 1 claim 9 , or multiple R.11. (canceled)12. A composition according to claim 9 , wherein Ris independently selected for Rand Rfrom the group consisting of hydrogen claim 9 , alkyl claim 9 , alkenyl claim 9 , and aryl claim 9 , each optionally substituted with 0 claim 9 , 1 claim 9 , or multiple R.13. A composition according to claim 12 , wherein Ris selected from the group consisting of —CH claim 12 , —CH(CH) claim 12 , and —CHOCHCH.14. A composition for the control of a fungal pathogen including at least one of the compositions of and a phytologically acceptable carrier material.15. A composition for the control of a fungal pathogen including at least one of the compositions of and a phytologically acceptable carrier material.16. (canceled)17. A ...

Подробнее
Номер записи: 24
14-01-2016 дата публикации

MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20160007601A1
Автор: Boebel Timothy A., Bravo-Altamirano Karla, Daeuble John F., Lu Yu, Meyer Kevin G., Nugent Benjamin M., Yao Chenglin
Принадлежит:

This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. The compound according to claim 1 , wherein X and Y are hydrogen.3. The compound according to claim 1 , wherein X is C(O)Rand Y is hydrogen.4. The compound according to claim 1 , wherein X is hydrogen and Y is Q.5. The compound according to claim 4 , wherein Ris hydrogen.6. The compound according to claim 4 , wherein Ris —C(O)Ror —CHOC(O)R.7. The compound according to claim 6 , wherein Ris alkyl or alkoxy claim 6 , each optionally substituted with 0 claim 6 , 1 claim 6 , or multiple R.8. The compound according to claim 7 , wherein Ris chosen from —CH claim 7 , —CH(CH) claim 7 , —CHOCHCH claim 7 , or —CHCHOCH.9. A composition for the control of a fungal pathogen including at least one of the compounds of and at least one additional compound selected from the group consisting of: a phytologically acceptable carrier material claim 1 , a second fungicide claim 1 , an insecticide claim 1 , a nematocides claim 1 , a miticide claim 1 , an arthropodicide claim 1 , a bactericide.10. The composition for the control of a fungal pathogen according to claim 9 , wherein the at least one additional compound is at least one phytologically acceptable carrier material.11Mycosphaerella graminicolaSeptoria triticiPuccinia triticinaPuccinia striiformisVenturia inaequalisUstilago maydisUncinula necatorRhynchosporium secalisMagnaporthe griseaPhakopsora pachyrhiziLeptosphaeria nodorumBlumeria graministriticiBlumeria graminishordeiErysiphe cichoracearumGlomerella lagenariumCercospora beticolaAlternaria solaniPyrenophora teres. The compositions according to claim 9 , wherein the fungal pathogen is at least one pathogen selected from the group consisting of: Leaf Blotch of Wheat (; anamorph: ) claim 9 , Wheat Brown Rust () claim 9 , Stripe Rust () claim 9 , Scab of Apple () claim 9 , Blister Smut of Maize () claim 9 , Powdery Mildew of Grapevine () claim 9 , Barley Scald () claim 9 , Blast of ...

Подробнее
Номер записи: 25
14-01-2016 дата публикации

MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20160007602A1
Автор: Bravo-Altamirano Karla, Daeuble John F., DeKorver Kyle A., DeLorbe Johnathan E., Heemstra Ron J., Meyer Kevin G., Yao Chenglin
Принадлежит:

This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. The compound according to claim 1 , wherein X and Y are hydrogen.3. The compound according to claim 2 , wherein Ris alkyl or aryl claim 2 , each optionally substituted with 0 claim 2 , 1 or multiple R.4. The compound according to claim 2 , wherein Ris hydrogen or alkyl claim 2 , each optionally substituted with 0 claim 2 , 1 or multiple R.5. The compound according to claim 1 , wherein X is C(O)Rand Y is hydrogen.6. The compound according to claim 5 , wherein Ris alkyl or aryl claim 5 , each optionally substituted with 0 claim 5 , 1 or multiple R.7. The compound according to claim 5 , wherein Ris hydrogen or alkyl claim 5 , each optionally substituted with 0 claim 5 , 1 or multiple R.8. The compound according to claim 1 , wherein X is hydrogen and Y is Q.9. The compound according to claim 8 , wherein Ris alkyl or aryl claim 8 , each optionally substituted with 0 claim 8 , 1 or multiple R.10. The compound according to claim 8 , wherein Ris hydrogen or alkyl claim 8 , each optionally substituted with 0 claim 8 , 1 or multiple R.11. The compound according to claim 9 , wherein Ris hydrogen.12. The compound according to claim 9 , wherein Ris —C(O)Ror —CHOC(O)R.13. The compound according to claim 12 , wherein Ris alkyl or alkoxy claim 12 , each optionally substituted with 0 claim 12 , 1 claim 12 , or multiple R.14. The compound according to claim 13 , wherein Ris —CH claim 13 , —CH(CH) claim 13 , —CHOCHCH claim 13 , or —CHCHOCH.15. A composition for the control of a fungal pathogen including at least one of the compounds of Formula I and at least one additional compound selected from the group consisting of: a phytologically acceptable carrier material claim 13 , a second fungicide claim 13 , an insecticide claim 13 , a nematocide claim 13 , a miticide claim 13 , an arthropodicide claim 13 , and a bactericide.16. The composition according to claim 15 , wherein the least one ...

Подробнее
Номер записи: 26
11-01-2018 дата публикации

COVALENT INHIBITORS OF CDK-7

Номер: US20180008604A1
Автор: CHEN Yi, Lou Yan
Принадлежит:

The disclosure includes compounds of Formula (I) 5. The compound according to or an N-oxide thereof claim 4 , or a pharmaceutically acceptable salt claim 4 , solvate claim 4 , polymorph claim 4 , tautomer claim 4 , stereoisomer claim 4 , an isotopic form claim 4 , or a prodrug thereof claim 4 , wherein Ris H claim 4 , —CH claim 4 , or CH—N(CH)CH; Ris H claim 4 , CH claim 4 , CF claim 4 , CN claim 4 , or halo.9. A pharmaceutical composition comprising a compound of Formula (I) or an N-oxide thereof as defined in claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , polymorph claim 1 , tautomer claim 1 , stereoisomer claim 1 , an isotopic form claim 1 , or a prodrug of said compound of Formula (I) or an N-oxide thereof claim 1 , and a pharmaceutically acceptable diluent or carrier.10. A method of treating a neoplastic disease claim 1 , comprising administering to a subject in need thereof an effective amount of a compound of Formula (I) or an N-oxide thereof as defined in claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , polymorph claim 1 , tautomer claim 1 , stereoisomer claim 1 , an isotopic form claim 1 , or a prodrug of said compound of Formula (I) or an N-oxide thereof. This application is a continuation of International Patent Application No. PCT/US2016/021722, filed on Mar. 10, 2016, which claims the benefit of the filing date, under 35 U.S.C. 119(e), of U.S. Provisional Application No. 62/135,147 filed on Mar. 18, 2015. The entire contents of each of the aforementioned applications are incorporated herein by reference.The members of the cyclin-dependent kinase (CDK) family play critical regulatory roles in proliferation. There are currently 20 known mammalian CDKs. While CDK7-13 have been linked to transcription, only CDK1, 2, 4, and 6 show demonstrable association with the cell cycle. Unique among the mammalian CDKs, CDK7 has consolidated kinase activities, regulating both the cell cycle and transcription. In ...

Подробнее
Номер записи: 27
12-01-2017 дата публикации

LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY INCLUDING THE SAME

Номер: US20170008872A1
Автор: BAE Ji Hong, OH Keun Chan
Принадлежит:

A liquid crystal composition including at least one of the liquid crystal molecules represented by Chemical Formulas 1 to 3: 6. The liquid crystal composition of claim 5 , comprisingabout 1 wt % to about 20 wt % of at least one of the liquid crystal molecules represented by Chemical Formula 1-1, Chemical Formula 1-2, Chemical Formula 2-1, Chemical Formula 2-2, Chemical Formula 3-1, and Chemical Formula 3-2, based on the entire weight of the composition.12. The liquid crystal display of claim 11 , comprising:about 1 wt % to about 20 wt % of at least one liquid crystal molecule represented by Chemical Formula 1-1, Chemical Formula 1-2, Chemical Formula 2-1, Chemical Formula 2-2, Chemical Formula 3-1, and Chemical Formula 3-2, based on the entire weight of the liquid crystal layer.13. The liquid crystal display of claim 12 , wherein:the liquid crystal molecules included in the liquid crystal layer are tilted in a direction parallel to branch electrodes when an electric field is not applied to the liquid crystal layer.14. The liquid crystal display of claim 13 , whereinthe liquid crystal molecules are tilted in a direction horizontal to an electric field when the electric field is applied to the liquid crystal layer. This application claims priority to and the benefit of Korean Patent Application No. 10-2015-0098634, filed on Jul. 10, 2015, and all the benefits accruing therefrom under 35 U.S.C. §119, the content of which in its entirety is herein incorporated by reference.(a) Technical FieldThe described technology relates generally to a liquid crystal composition and a liquid crystal display including the same.2. Description of the Related ArtLiquid crystal displays (“LCDs”) are widely used flat panel displays, which include two display panels facing each other, a liquid crystal layer interposed between two display panels, and a field generating electrode such as a pixel electrode and a common electrode positioned on at least one of the two display panels.In an LCD, ...

Подробнее
Номер записи: 28
14-01-2021 дата публикации

COMPOUNDS AND METHODS FOR TREATING FIBROSIS OR CANCER

Номер: US20210009551A1
Автор: Backes Bradley J., Chapman Harold A., Wei Ying
Принадлежит:

Provided herein, inter alia, are methods and compounds for treating a pulmonary disease, fibrosis, or cancer. 3. The compound of claim 1 , wherein Ris —NH claim 1 , —OH claim 1 , or substituted or unsubstituted heteroalkyl.4. (canceled)5. The compound of claim 1 , wherein Ris —NH claim 1 , —OH claim 1 , or substituted or unsubstituted heteroalkyl.6. (canceled)7. The compound of claim 1 , wherein Ris —NH claim 1 , —OH claim 1 , or substituted or unsubstituted heteroalkyl.8. (canceled)9. The compound of claim 1 , wherein Ris —NH claim 1 , —OH claim 1 , or substituted or unsubstituted heteroalkyl.10. (canceled)11. The compound of claim 1 , wherein Ris —NH claim 1 , —OH claim 1 , or substituted or unsubstituted heteroalkyl.12. (canceled)13. The compound of claim 1 , wherein Ris —NH claim 1 , —OH claim 1 , or substituted or unsubstituted heteroalkyl.14. (canceled)17. (canceled)18. (canceled)19. (canceled)20. The compound of claim 1 , wherein Ris independently —COOR claim 1 , —NRC(O)OR claim 1 , or —C(O)R.2128.-. (canceled)29. The compound of claim 1 , wherein Ris independently hydrogen.30. The compound of claim 1 , wherein Ris independently hydrogen.31. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable excipient.32. A method of reducing the level of activity of zinc finger protein Snail1 in a subject claim 1 , said method comprising administering an effective amount of a compound of to the subject.33. A method of reducing the level of activity of Lysyl oxidase homolog 2 (LOXL2) in a subject claim 1 , said method comprising administering an effective amount of a compound of to the subject.34. A method of inhibiting collagen cross-linking in a subject claim 1 , said method comprising administering an effective amount of a compound of to the subject.35. A method of treating fibrosis claim 1 , said method comprising administering to a subject in need thereof an effective amount of a compound of .36. (canceled)37. (canceled)38. A method ...

Подробнее
Номер записи: 29
28-01-2016 дата публикации

Prodrugs of Fluorinated Mevalonates to Inhibit the Mevalonate Pathway of Streptococcus pneumoniae

Номер: US20160024042A1
Автор: Kang Soosung, Leyh Thomas S., Silverman Richard B., Watanabe Mizuki
Принадлежит:

Fluorinated prodrug compounds as can be used for selective streptococcal mevalonate pathway inhibition. 2. The compound of wherein X is selected from NH and O; and Ris selected from fluoromethyl and trifluoromethyl moieties.3. The compound of wherein Ris selected from mono- and polyfluoro-substituted arylalkyl moieties.4. The compound of wherein Ris selected from mono- and difluoro-substituted benzyl moieties.5. The compound of in at least one of human plasma and contact with an enzyme in a streptococcal mevalonate biosynthetic pathway.7. The compound of wherein X is selected from NH and O; and Ris selected from fluoromethyl and trifluoromethyl moieties.8. The compound of wherein Ris selected from aryl claim 7 , mono- and polyfluoroaryl claim 7 , arylalkyl claim 7 , mono- and polyfluoroarylalkyl moieties.9. The compound of wherein Ris selected from phenyl claim 8 , mono- and polyfluorophenyl claim 8 , benzyl claim 8 , monofluorobenzyl and polyfluorobenzyl moieties.11. The compound of wherein X is selected from NH and O; and Ris independently selected from fluoromethyl and trifluoromethyl moieties.12. The compound of where Ris selected from arylalkyl claim 11 , mono- and polyfluoro-substituted arylalkyl moieties.13. The compound of wherein Rand Rare independently selected from H and alkyl moieties.14. The compound of wherein at least one of Rand Ris methyl.16. The compound of wherein X is selected from NH and O; and Ris selected from fluoromethyl and trifluoromethyl moieties.17. The compound of wherein Ris selected from alkyl claim 16 , mono- and polyfluoro-substituted alkyl claim 16 , aryl claim 16 , mono- and polyfluoro-substituted aryl claim 16 , arylalkyl claim 16 , mono- and polyfluoro-substituted arylalkyl moieties.18. The compound of wherein X is O; Ris selected from alkyl claim 15 , aryl and arylalkyl moieties; and Rand Rare independently selected from H and acetyl moieties.19. The compound of wherein at least one of Rand Ris acetyl.21. The compound of ...

Подробнее
Номер записи: 30
25-01-2018 дата публикации

KETAL COMPOUNDS AND USES THEREOF

Номер: US20180022724A1
Автор: Bechtold Kevin Jon
Принадлежит:

Various esterified alkyl ketal ester or hydroxyalkyl ketal ester products are useful as components of organic polymer compositions. The ketal esters are produced in certain transesterifications between alkyl ketal esters and/or hydroxyalkyl ketal esters and polyols, aminoalcohols, polyamines and/or polycarboxylic acids. The products are excellent plasticizers for a variety of organic polymers, notable poly(vinylchloride) plastisols. 2. The compound of claim 1 , wherein Rcontains one or more ether or ester groups.3. The compound of claim 1 , wherein Ris C-Calkyl.5. A mixture comprising two or more compounds of .6. A composition comprising the compound of claim 1 , and an organic polymer.7. The composition of claim 6 , which has a glass transition temperature at least 30° C. lower than a glass transition temperature of the polymer.8. The composition of claim 6 , wherein the compound constitutes from 0.1 to 90% of the combined weight of the compound and the polymer.9. The composition of claim 6 , wherein the polymer is a thermoplastic.10. The composition of claim 6 , wherein the polymer is a thermoset.11. The composition of claim 6 , wherein the polymer comprises a poly(vinyl chloride) claim 6 , polyhydroxyalkanoate claim 6 , a poly(lactic acid) claim 6 , a polystyrene claim 6 , a polyurethane claim 6 , a polyurea claim 6 , a polyurea-urethane claim 6 , a polycarbonate claim 6 , an acrylic polymer claim 6 , a styrene-acrylic polymer claim 6 , a vinyl-acrylic polymer claim 6 , an ethylene-vinyl acetate polymer claim 6 , a polyester claim 6 , a polyamide claim 6 , a polyether claim 6 , a polybutadiene claim 6 , an acrylonitrile-butadiene-styrene copolymer claim 6 , a styrene-butadiene-styrene copolymer claim 6 , a polyvinyl acetate claim 6 , an elastomer claim 6 , or homopolymers thereof claim 6 , or random claim 6 , graft claim 6 , or block copolymers thereof claim 6 , or blends or mixtures thereof.12. The composition of claim 6 , wherein the compound is melt blended or ...

Подробнее
Номер записи: 31
17-02-2022 дата публикации

POLYMER-PARTICLE LIGHT-CLEAVABLE CARRIER SYSTEMS FOR PHOTODYNAMIC THERAPY

Номер: US20220047705A1
Автор: Albrecht Volker, ANDERSKI Juliane, BIRNBAUM Wolfgang, KUCKLING Dirk, LANGER Klaus, MAHLERT Laura, MULAC Dennis, SUN Jingjiang, Wiehe Arno, WIELAND Gerhard Dieter
Принадлежит:

The present invention generally relates to the formation, chemistry and application of biologically active compositions. More particularly, the present invention relates to certain dyes, specifically porphyrin and chlorin derivatives, in combination with inventive polymers, i.e. light-cleavable polymers, that can be used as photosensitizer compositions for a wide range of light irradiation treatments such as photodynamic therapy of cancer, infections and other diseases. The dye derivatives may either be adsorbed on, or incorporated in, or attached to specific polymers, which as well form part of the invention. 2. A pharmaceutical composition , comprising{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a light-cleavable polymer formed as nanometer particles, wherein the light-cleavable polymer comprises a polymer according to ;'}a therapeutically effective amount of a photosensitizer; andoptionally one or more auxiliary agents, such as a stabilizer.3. The pharmaceutical composition according to claim 2 , characterized in that the photosensitizer is a tetrapyrrole-based photosensitizer.5. The pharmaceutical composition according to claim 2 , characterized in that the stabilizing agent is selected from the group consisting of polyvinyl alcohol claim 2 , polysorbate claim 2 , poloxamer claim 2 , and albumin.6. The pharmaceutical composition according to claim 2 , characterized in that the photosensitizer is present in an amount of 1 to 500 μg per mg light cleavable polymer.8. A method of forming a pharmaceutical composition according to claim 2 , comprising the steps of:a) dissolving the light-cleavable polymer alone or in combination with a further polymer in an organic solvent to form a polymer solution;b) optionally dissolving a stabilizer in an aqueous solution to form a stabilizing solution;c) optionally filtering said polymer solution and optionally said stabilizing solution through a filtration unit;d) mixing the optionally filtered polymer solution with an ...

Подробнее
Номер записи: 32
01-05-2014 дата публикации

2,2'-Binaphthalene Ester Chiral Dopants for Cholesteric Liquid Crystal Displays

Номер: US20140117284A1
Автор: Donald R. Diehl, Erica N. Montbach
Принадлежит: Kent Displays Inc, KENT STATE UNIVERSITY

A liquid crystal composition comprising a chiral dopant compound represented by the following structure (Structure 1): wherein: R1 and R2 are independently hydrogen, —(C═O)R9, —(C═O)R10, alkyl, aryl, alkaryl, alkenyl, cycloalkyl, alkoxyaryl, or heterocyclic all either substituted or unsubstituted, or combine to form a carbocyclic or heterocyclic ring; R3 is hydrogen, halogen, cyano, alkoxy, NHCOR9, NHSO2R9, COOR9, OCOR9, aryl, alkyl, alkenyl, cycloalkyl, or heterocyclic all either substituted or unsubstituted; R4 is hydrogen, alkyl, aryl, alkenyl, cycloalkyl, or heterocyclic all either substituted or unsubstituted; R5, R6, R7, and R8 are independently hydrogen, halogen, cyano, alkoxy, NHCOR9, NHSO2R9, COOR9, OCOR9, aryl, alkyl, alkenyl, cycloalkyl, alkoxyaryl or heterocyclic all either substituted or unsubstituted, or combine with each other, or R5 can combine with R4 to form a carbocyclic or heterocyclic ring; R9 and R10 are independently alkyl, alkoxy, aryl, naphthyl, styryl, alkenyl, cycloalkyl, alkoxyaryl, cycloalkoxy, or heterocyclic all either substituted or unsubstituted, or combine to form a carbocyclic or heterocyclic ring. Also featured are liquid crystal compositions comprising a chiral dopant compound represented by any of Structure 2-4.

Подробнее
Номер записи: 33
31-01-2019 дата публикации

Method for producing monomers from isomeric mixtures

Номер: US20190031638A1
Автор: BEYER Silvia, DAVE Gaurang, DILLMANN Hans-Jürgen, HARTMANN Patrik, HERZOG Volker, Knebel Joachim, KÖMMELT Sabine, MERBACH Ralf, SCHÜTZ Thorben, Trocha Martin
Принадлежит: Evonik Röhm GmbH

A process produces a (meth)acrylate ester mixture. The process includes reacting a glycerol formal isomer mixture with an alkyl (meth)acrylate in the presence of a catalyst. 1. A process for producing a (meth)acrylate ester mixture , the process comprising:reacting a glycerol formal isomer mixture with an alkyl (meth)acrylate in the presence of a catalyst.2. The process according to claim 1 , whereinthe glycerol formal isomer mixture is a mixture having an isomer ratio of 5-membered ring isomer to 6-membered ring isomer of 20:80 to 70:30.3. The process according to claim 2 , whereina homopolymer, comprising reacted units of at least one (meth)acrylate ester isomer from the (meth)acrylate ester mixture, has a glass transition temperature Tg of from 75° C. and 90° C.4. The process according to claim 1 , whereinthe catalyst is at least one member selected from the group consisting of a titanium alkoxide, a zirconium complex, a tin compound, and a mixture of lithium hydroxide and calcium oxide.5. The process according to claim 1 , whereinsaid reacting is performed at a temperature of from 30° C. and 180° C.67-. (canceled)8. A (meth)acrylate ester mixture obtained by a process according to claim 1 , wherein the (meth)acrylate ester has a vapor pressure of from 0.001 and 5 hPa.9. A process of producing a polymer claim 1 , the process comprising:{'claim-ref': {'@idref': 'CLM-00008', 'claim 8'}, 'polymerizing the (meth)acrylate ester mixture according to .'}10. A process of producing a coating composition claim 1 , the process comprising:{'claim-ref': {'@idref': 'CLM-00008', 'claim 8'}, 'polymerizing the (meth)acrylate ester mixture according to to obtain a polymer; and'}adding the polymer to a coating precursor composition to obtain the coating composition. The inversion relates to a process for producing (meth)acrylic esters of isomeric alcohols obtained by reaction of glycerol with formaldehyde (hydroxyl-substituted dioxanes and dioxolanes) in high-yield using titanium-, ...

Подробнее
Номер записи: 34
09-02-2017 дата публикации

Production of 2-substituted 4-hydroxy-4-methyltetrahydropyrans having stable odoriferous quality

Номер: US20170037021A1
Автор: Axel Salden, Karl Beck, Klaus Ebel, Martine DEHN, Ralf Pelzer, Timon STORK
Принадлежит: BASF SE

The present invention relates to a method for the production of 2-substituted 4-hydroxy-4-methyltetrahydropyrans from the acid-catalyzed reaction of 3-methylbut-3-ene-1-ol with an aldehyde, a stable odoriferous quality being achieved and avoiding off-odors that interfere with the odor sensation.

Подробнее
Номер записи: 35
19-02-2015 дата публикации

Method for preparing cyclopropane derivatives

Номер: US20150051394A1
Автор: E.J.N. Remy LITJENS, Eleonora KISS, Erwin Blomsma, Serge DE BRUIJN
Принадлежит: Aratana Therapeutics NV

The present invention relates to the preparation of cyclopropane derivatives, in particular 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-4,8-dihydro-1H-purin-6-one, especially via the [(1S,7R)-4-phenyl-3,5-dioxabicyclo[5.1.0]octan-1-yl]methanol intermediate.

Подробнее
Номер записи: 36
04-03-2021 дата публикации

Diamine Compound with Meldrum's Acid Group and Related Polymer Thereof

Номер: US20210061782A1
Автор: Huang Chien-Ho, Liu Ying-Ling
Принадлежит:

The present disclosure provides a diamine compound, which includes a structure represented by formula (I). Formula (I) is defined as in the specification. The present disclosure further provides an amide bond-containing polymer, a polyimide, a polybenzoxazine, a thermosetting resin and a copolymerized thermosetting resin prepared by the diamine compound including the structure represented by formula (I). 2. The diamine compound of claim 1 , wherein in the formula (I) claim 1 , Rand Rare benzyl groups.3. An amide bond-containing polymer material prepared by a ring-opening self-polymerization of the diamine compound of .4. A polyimide prepared by a condensation reaction of the diamine compound of and a dianhydride monomer.6. A polybenzoxazine prepared by a condensation reaction of the diamine compound of claim 1 , a diphenol monomer and polyoxymethylene.8. A thermosetting resin prepared by self-crosslinking of the diamine compound of .9. A copolymerized thermosetting resin prepared by adding the diamine compound of to a thermosetting resin system.10. The copolymerized thermosetting resin of claim 9 , wherein the thermosetting resin system is epoxy resin claim 9 , phenolic resin claim 9 , polyester resin claim 9 , benzoxazine resin claim 9 , carbamide resin or polyurethane resin. This application claims priority to Taiwanese Patent Application No. 108131113 filed Aug. 29, 2019, the disclosure of which is hereby incorporated by reference in its entirety.The present disclosure relates to a diamine compound and related polymer thereof. More particularly, the present disclosure relates to a diamine compound, an amide bond-containing polymer material, a polyimide, a polybenzoxazine, a thermosetting resin and a copolymerized thermosetting resin with a Meldrum's acid group.Nowadays, the polymers have been widely used in the semiconductor industry, the automotive industry, the photoelectric industry, the biomedical materials, and the communication materials. Therefore, in the ...

Подробнее
Номер записи: 37
20-02-2020 дата публикации

Flash and Glow 1,2-Dioxetanes

Номер: US20200056222A1
Автор: Edwards Brooks, Mihali Albana, Wang Zhixian
Принадлежит:

Compounds having chemiluminescent flash and glow properties. Also disclosed are methods using the compounds to generate light, detect and/or quantify enzymes, antigens, and/or nucleic acids. Also disclosed are kits relating to these compounds. 216.-. (canceled)17. The compound of claim 1 , wherein the cleavage of the bond cleavable by an enzyme moiety results in the generation of light at 25° C. which reaches a maximum in less than about 15 minutes.18. The compound of claim 17 , wherein the generation of light reaches a maximum in less than about 10 minutes.19. The compound of claim 17 , wherein the generation of light reaches a maximum in less than about 5 minutes.20. The compound of claim 1 , wherein the cleavage of the bond cleavable by an enzyme moiety results in the generation of light at 37° C. which reaches a maximum in less than about 15 minutes.21. The compound of claim 20 , wherein the generation of light reaches a maximum in less than about 10 minutes.22. The compound of claim 20 , wherein the generation of light reaches a maximum in less than about 5 minutes.24. A method for generating light claim 20 , comprising the steps of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(a) providing the compound of ;'}(b) providing an enzyme complex comprising an enzyme moiety which is capable of cleaving the compound;(c) contacting the enzyme complex with the compound to form a reaction mixture; and,(d) allowing the reaction mixture to generate light.2584.-. (canceled)86. An assay method for determining the presence and/or amount of an enzyme in a sample claim 20 , comprising the steps of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(a) providing the compound of ;'}(b) providing a sample suspected of comprising the enzyme which is capable of cleaving the compound so that it decomposes and generates light;(c) contacting the sample with the compound to form a reaction mixture; and,(d) detecting the light generated by the reaction mixture after addition of the ...

Подробнее
Номер записи: 38
29-05-2014 дата публикации

METHODS OF USING PYRUVATE KINASE ACTIVATORS

Номер: US20140148444A1
Автор: Su Shin-San M.
Принадлежит: AGIOS PHARMACEUTICALS, INC

Described herein are compounds that activate pyruvate kinase, for use in a method for increasing lifetime of the red blood cells, for regulating 2,3-diphosphoglycerate levels in blood and for treating sickle cell anemia. 2. The method of claim 1 , wherein the compound is added directly to whole blood or packed cells extracorporeally.3. The method of claim 1 , wherein the pharmaceutical composition is administered to a patient in need thereof.7. The method of claim 1 , wherein Rand Rare phenyl substituted with one or more substituents selected from the group consisting of C-Calkyl claim 1 , C-Ctrihaloalkyl claim 1 , heterocyclyl claim 1 , heteroaryl claim 1 , alkylenedioxy claim 1 , OR claim 1 , SR claim 1 , NRR claim 1 , NCOR claim 1 , OCOR claim 1 , SCOR claim 1 , SOR claim 1 , SOR claim 1 , SONRR claim 1 , NO claim 1 , B(OH) claim 1 , CN claim 1 , and halogen claim 1 ,{'sup': 3', '4, 'sub': 1', '10, 'Rand Rare independently selected from the group consisting of H, C-Calkyl, and F, or, taken together, form C═O, and'}{'sup': 5', '7', '10, 'sub': 1', '10, 'Rand Rto Rare independently H, C-Calkyl, or F.'}8. The method of claim 1 , wherein Rand Rare phenyl substituted with one or more substituents selected from the group consisting of C-Calkyl claim 1 , C-Ctrihaloalkyl claim 1 , heterocyclyl claim 1 , heteroaryl claim 1 , alkylenedioxy claim 1 , CN claim 1 , and halogen claim 1 , and Rto Rare H.9. The method of claim 1 , wherein X is N.10. The method of claim 1 , wherein n is 1.11. The method of claim 1 , wherein Ris selected from the group consisting of phenyl claim 1 , 4-methylphenyl claim 1 , 2-methylphenyl claim 1 , 2-fluorophenyl claim 1 , 4-chlorophenyl claim 1 , 4-fluorophenyl claim 1 , 4 claim 1 ,2-difluorophenyl claim 1 , 2 claim 1 ,6-difluorophenyl claim 1 , 2 claim 1 ,4 claim 1 ,5-trifluorophenyl claim 1 , 4-chloro-2-fluorophenyl claim 1 , 3-chloro-2-fluorophenyl claim 1 , 4-trifluoromethylphenyl claim 1 , 3-trifluoromethylphenyl claim 1 , 2 claim 1 ,6- ...

Подробнее
Номер записи: 39
15-03-2018 дата публикации

COMPOUNDS HAVING ANTIOXIDANT ACTIVITY AGAINST FREE RADICALS AND ANTI-INFLAMMATORY ACTIVITY, AND CORRESPONDING PHARMACEUTICAL OR COSMETIC COMPOSITIONS FOR SKIN CARE

Номер: US20180072698A1
Автор: Baroni Sergio, Benedusi Anna, Giuliani Giammaria, MARZANI Barbara
Принадлежит:

The invention relates to compounds having general formula (I): where R═H, CH—OH, CH—O—CO—CH, CH—O—CO—Ph (Ph=phenyl) R′═H, CH—O—CO—CH, CH—O—CO-Ph (Ph=phenyl) Ar=phenyl, 3-methoxy-4-hydroxy phenyl, 2-furyl. These are compounds having antioxidant activity against free radicals together with anti-inflammatory activity, the compounds being useful as active ingredients for the preparation of pharmaceutical dermatological or cosmetic compositions for skin care. 113-. (canceled)15. The compound according to claim 14 , wherein said compound is chosen among sorbitylbenzal claim 14 , xylitilfurfural claim 14 , sorbitylvanillinal claim 14 , tetrabenzoyl sorbitylfurfural claim 14 , and tetraacetyl sorbitylfurfural.17. The method according to wherein the compound of formula (I) is chosen among sorbitylbenzal claim 16 , xylitilfurfural claim 16 , sorbitylvanillinal claim 16 , tetrabenzoyl sorbitylfurfural claim 16 , and tetraacetyl sorbitylfurfural.19. The composition according to characterized in that the compound of formula (I) is chosen among sorbitylbenzal claim 18 , xylitilfurfural claim 18 , sorbitylvanillinal claim 18 , tetrabenzoyl sorbitylfurfural claim 18 , and tetraacetyl sorbitylfurfural.21. The composition according to wherein the compound of formula (I) is chosen among sorbitylbenzal claim 20 , xylitilfurfural claim 20 , sorbitylvanillinal claim 20 , tetrabenzoyl sorbitylfurfural claim 20 , and tetraacetyl sorbitylfurfural.22. The composition according to comprising said active principle in an amount ranging from 0.001 to 2.0% w/w based on the weight of the composition.26. The composition according to comprising said active principle in an amount ranging from 0.001 to 2.0% w/w based on the weight of the composition. The present invention relates to compounds having antioxidant activity against free radicals together with anti-inflammatory activity, these compounds being useful as active ingredients for the preparation of pharmaceutical dermatological or cosmetic ...

Подробнее
Номер записи: 40
12-06-2014 дата публикации

KETAL ESTER DERIVATIVES

Номер: US20140163127A1
Автор: BADARINARAYANA Vivek, MULLEN Brian Daniel, SELIFONOV Sergey, WICKS Douglas Alan
Принадлежит: SEGETIS, INC.

The present disclosure relates to the preparation of acrylate, alkacrylate, allyl, and polycarbonate derivatives of hydroxy ketal esters, and uses thereof. 2. The compound of wherein Rfurther comprises one or more additional functional groups comprising halogen claim 1 , tertiary amine claim 1 , carbonate claim 1 , ether claim 1 , carboxylic acid claim 1 , carboxylic ester claim 1 , carbonyl claim 1 , urethane claim 1 , imide claim 1 , amide claim 1 , or a combination thereof.3. The compound of wherein Ris —(CH)— claim 1 , Ris —CH claim 1 , and Ris the residue of glycerol.4. The compound of wherein Ris the residue of a diacid claim 1 , the diacid comprising oxalic acid claim 1 , malonic acid claim 1 , succinic acid claim 1 , adipic acid claim 1 , pimellic acid claim 1 , suberic acid claim 1 , dodecane-dioic acid claim 1 , azelaic acid claim 1 , a dimer acid claim 1 , sebacic acid claim 1 , or o claim 1 , m claim 1 , or p-phthalic acid.5. The compound of wherein β is 1.6. The compound of wherein β is 2.7. The compound of wherein Ris the ketal residue and R is —(CH)— claim 2 , R is —CH claim 2 , and R is the residue of 1 claim 2 ,2-propanediol or 1 claim 2 ,2-ethanediol.8. The compound of wherein one or more α is between about 1 and 4.11. The formulation of claim 9 , wherein one or more γ is between about 1 and 10 and repeat units IA claim 9 , IB claim 9 , or both further comprise one or more repeat units comprising a polyurethane moiety.13. The compound of wherein R claim 12 , R claim 12 , or both further comprise one or more halogen claim 12 , tertiary amine claim 12 , amide claim 12 , carbonate claim 12 , ether claim 12 , ester claim 12 , keto claim 12 , ketal claim 12 , or urethane functionalities.14. The compound of wherein β is 1 or 2.15. The compound of wherein Ris —(CH)— claim 12 , and Ris —CH claim 12 , and Ris the residue of glycerol.16. The compound of wherein about 20% by weight or more of the compound is biomass based.17. (canceled)18. (canceled)19. ( ...

Подробнее
Номер записи: 41
21-03-2019 дата публикации

CHEMICAL TOOLS FOR IMAGING PHOSPHOLIPASE D ACTIVITY

Номер: US20190085373A1
Автор: BASKIN Jeremy, BUMPUS Timothy, LIANG Dongjun
Принадлежит:

A method for detecting phospholipase D (PLD) activity in a cell, comprising: (i) stimulating endogenous PLD in said cell for said PLD to catalyze a transphosphatidylation reaction between phosphatidylcholine or a derivative thereof and an exogenous functionalized alcohol to form a phosphatidyl alcohol, wherein the functionalized alcohol possesses a first functional group that can react with and form a bond to a functionalized detectable label having a second functional group reactive with the first functional group, and said phosphatidyl alcohol contains said first functional group in available form; (ii) reacting said phosphatidyl alcohol with said functionalized detectable label under conditions where said functionalized detectable label reacts, via its second functional group, with the first functional group to form a linkage between said detectable label and said phosphatidyl alcohol so as to form a labeled phosphatidyl alcohol containing said detectable label; and (iii) detecting said labeled phosphatidyl alcohol. 1. A method for detecting phospholipase D (PLD) activity in a cell , the method comprising:(i) stimulating endogenous PLD in said cell while said cell is in contact with an exogenous functionalized alcohol containing at least one carbon atom in order for said PLD to catalyze a transphosphatidylation reaction between phosphatidylcholine or a derivative thereof and said exogenous functionalized alcohol to form a phosphatidyl alcohol, wherein said exogenous functionalized alcohol possesses a first functional group that can react with and form a bond to a functionalized detectable label having a second functional group reactive with the first functional group, and said phosphatidyl alcohol contains said first functional group in available form, as provided by the exogenous functionalized alcohol;(ii) reacting said phosphatidyl alcohol with said functionalized detectable label under conditions where said functionalized detectable label reacts, via its ...

Подробнее
Номер записи: 42
30-03-2017 дата публикации

MACROCYCLIC COMPOUNDS, POLYMERS, AND METHODS FOR MAKING SAME

Номер: US20170088536A1
Автор: Foley Patrick, YANG Yonghua
Принадлежит:

The application relates to macrocyclic compounds and related polymers, as well as to processes for synthesizing them, e.g., using olefins as starting material. 24.-. (canceled)5. The compound of claim 1 , wherein claim 1 , for the compound of Formula I claim 1 , the number of atoms comprising the ring structure is between 13 and 19.6. The compound of claim 1 , wherein X is O.7. The compound of claim 1 , wherein X is NH.8. The compound of claim 1 , wherein Z is hydrogen.10. The compound of claim 1 , wherein Ris optionally substituted linear CCalkyl branched C-Calkyl claim 1 , unsubstituted linear C-Calkyl claim 1 , optionally substituted linear C-Calkenyl claim 1 , unsubstituted linear C-Calkenyl or branched C-Calkenyl.1113.-. (canceled)14. The compound of claim 1 , wherein Ris optionally substituted linear CCalkyl claim 1 , unsubstituted linear CCalkyl or branched C-Calkyl.15. The compound of claim 1 , wherein Ris linear CCalkyl or branched C-Calkyl substituted with one or more hydroxyl groups.16. (canceled)17. The compound of claim 1 , wherein Ris optionally substituted linear C-Calkenyl claim 1 , unsubstituted linear C-Calkenyl or branched C-Calkenyl.18. (canceled)19. The compound of claim 1 , wherein Ris optionally substituted linear C-Calkynyl claim 1 , unsubstituted linear C-Calkynyl or branched C-Calkynyl.20. (canceled)24. (canceled)25. The method of claim 23 , further comprising an amidation step claim 23 , wherein a compound of Formula I claim 23 , wherein X is O claim 23 , reacts with NHunder an elevated pressure to obtain a corresponding compound of Formula I claim 23 , wherein X is NH.26. (canceled)27. The method of claim 23 , wherein the esterification step is performed at a first temperature that is greater than room temperature claim 23 , and the etherification step is performed at a second temperature that is lower than the first temperature.2833.-. (canceled)34. The method of claim 23 , wherein the etherification step is quenched with a base.35. ( ...

Подробнее
Номер записи: 43
19-03-2020 дата публикации

METHOD FOR PRODUCING GLYCERIC ACID ESTER

Номер: US20200087290A1
Автор: AOKI Takashi
Принадлежит: KAO CORPORATION

The present invention relates to providing a novel glyceric acid ester which can be produced in a high yield and is expected to be applied as a synthetic intermediate, and a method of producing the same. In addition, the present invention relates to providing a novel glyceric acid ester which exhibits a high recovery in a water-washing step after the reaction and a small work load at the time of production, and is expected to be applied as a synthetic intermediate, and a method of producing the same. The present invention provides a method of producing a compound represented by the following formula (II), including a step of oxidatively esterifying a compound represented by the following formula (I): 3. The production method according to claim 1 , wherein in the step of performing oxidative esterification claim 1 , a compound selected from an organic nitroxyl radical claim 1 , an N-hydroxy form thereof claim 1 , and a salt containing an oxo ammonium cation of them claim 1 , an oxidizing agent claim 1 , and a base are used.4. The production method according to claim 3 , wherein the base is a heterocyclic aromatic amine having a pyridine skeleton.6. The production method according to claim 3 , wherein the oxidizing agent is an oxidizing agent composed of a compound containing a halogen.7. The production method according to claim 1 , comprising claim 1 , after the step of performing oxidative esterification claim 1 , a step of separating the compound represented by the formula (II).8. The production method according to claim 7 , wherein the separation in the step of separating the compound represented by the formula (II) is separation through distillation.9. A method of producing glyceric acid claim 1 , a glyceric acid salt claim 1 , or a deprotected glyceric acid ester claim 1 , comprising a step of producing the compound represented by the formula (II) by the production method according to claim 1 , and a step of subjecting the compound represented by the formula (II ...

Подробнее
Номер записи: 44
28-03-2019 дата публикации

FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION

Номер: US20190092720A1
Автор: BLOCK Timothy M., Du Yanming, Guo Ju-Tao, Xu Xiaodong
Принадлежит:

Pharmaceutical compositions of the invention comprise functionalized benzamide derivatives useful as pregenomic RNA encapsidation inhibitors, useful for the treatment of Hepatitis B virus (HBV) infection. 2. The compound of claim 1 , wherein X is CH and n is 1.3. The compound of claim 1 , wherein X is S and n is 0.4. The compound of claim 1 , wherein m is 0.5. The compound of claim 1 , which is selected from the group consisting of:3,4-Dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid (3-chloro-phenyl)-amide;3,4-Dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid (3,4-difluoro-phenyl)-amide;3,4-Dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid (3-chloro-4-fluoro-phenyl)-amide;or a hydrate, solvate, or salt thereof.6. A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and at least one compound of .7. A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and at least one compound selected from the group consisting of:3,4-Dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid (3-chloro-phenyl)-amide;3,4-Dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid (3,4-difluoro-phenyl)-amide;3,4-Dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid (3-chloro-4-fluoro-phenyl)-amide;or a hydrate, solvate, or salt thereof.8. A method for treating or ameliorating a disease or disorder that involves pregenomic RNA encapsidation claim 1 , the method comprising administering to a subject a therapeutically effective amount of at least one compound of .9. The method of claim 8 , wherein the disease or disorder is hepatitis B.10. The method of claim 8 , wherein the at least one compound is administered as part of a pharmaceutical composition further comprising at least one pharmaceutically acceptable excipient.11. A method of treating or ameliorating hepatitis B in a subject infected with hepatitis B virus claim 1 , the method comprising administering to the subject a therapeutically amount of at least one ...

Подробнее
Номер записи: 45
19-03-2020 дата публикации

TUNED SYNTHETIC DENDRIMER CALIBRANTS FOR MASS SPECTROMETRY

Номер: US20200090917A1
Автор: Grayson Scott
Принадлежит:

Provided are synthetic dendrimer calibrants for mass spectrometry. The calibrants are distinguished by their relative case and rapidity of synthesis, comparatively low cost, long shelf life, high purity, and amenability to batch synthesis as mixtures. The latter characteristic enables parallel preparation of higher molecular weight compounds displaying useful distributions of discrete molecular weights, thereby providing multi-point mass spectrometry calibration standards. Methods of making, tuning and using said calibrants are provided. 1. A composition comprising:a first dendrimer comprising a first core molecule, wherein said first core molecule is selected from the group consisting of: a molecule comprising between 1 and 8 alcohol functionalities, a molecule comprising between 1 and 8 amine functionalities, and a molecule comprising at least one amine functionality and at least one alcohol functionality wherein the combined number of amine and alcohol functionalities of said first core molecule is at least 2 but no greater than 8; a second dendrimer comprising a second core molecule, wherein said second core molecule is selected from the group consisting of: a molecule comprising between 1 and 8 alcohol functionalities, a molecule comprising between 1 and 8 amine functionalities, and a molecule comprising at least one amine functionality and at least one alcohol functionality wherein the combined number of amine and alcohol functionalities of said second core molecule is at least 2 but no greater than 8; and wherein said first core molecule has a different number of total alcohol functionalities and amine functionalities than said second core molecule.216.-. (canceled)17. A method of manufacturing , comprising the steps of:providing a composition comprising a first core molecule wherein said first core molecule is selected from the group consisting of: a molecule comprising between 1 and 8 alcohol functionalities, a molecule comprising between 1 and 8 amine ...

Подробнее
Номер записи: 46
03-07-2014 дата публикации

SYNTHESIS AND USE OF ISOTOPICALLY LABELED MACROCYCLIC COMPOUNDS

Номер: US20140186873A1
Автор: Johnson Peter Lee, JR. Ronald, Meyer Kevin G., Ross
Принадлежит:

Disclosed herein are isotopically labeled antifungal antibiotics and related compounds. Also disclosed are methods for synthesizing these isotopically labeled molecules and using the same to study the distribution of these compounds in the biosphere as well as the products formed by the breakdown of these isotopically labeled compounds. 4. The compound according to claim 1 , wherein Ris H.9. The compound according to claim 5 , wherein Ris Ph-C10. The compound according to claim 5 , wherein Ris Ph-UL-C.12. The method according to claim 11 , wherein the compound is (a) and the sample is a portion of a plant.13. The method according to claim 11 , wherein the compound is (a) and the sample is from a surface adjacent to a plant.14. The method according to claim 11 , wherein the compound is (a) and the sample is from a material that is in communication with a surface adjacent to a plant.15. The method according to claim 11 , where the compound is (a) and the isotopically labeled signature is contained in a portion of said compound.16. The method according to claim 11 , wherein the compound is (b) and the sample is a portion of a plant.17. The method according to claim 11 , wherein the compound is (b) and the sample is from a surface adjacent to a plant.18. The method according to claim 11 , wherein the compound is (b) and the sample is from a material that is in communication with a surface adjacent to a plant.19. The method according to claim 11 , where the compound is (b) and the isotopically labeled signature is contained in a portion of said compound. This application claims the benefit of U.S. Provisional Patent Application Ser. No. 61/747,699 filed Dec. 31, 2012, which is expressly incorporated by reference herein.Aspects of the invention include the preparation and use of isotopically labeled compounds including radiolabeled forms of the antifungal antibiotic UK-2A and related compounds.Isotopically labeled compounds are important tools in characterizing the role ...

Подробнее
Номер записи: 47
14-05-2015 дата публикации

LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY

Номер: US20150129800A1
Автор: Rillich Malgorzata, WITTEK Michael
Принадлежит:

The instant invention relates to mesogenic media comprising one or more compounds of formula D 4. Medium according to claim 3 , characterized in that it comprises one or more compounds of formula D-1.5. Medium according to claim 3 , characterized in that it comprises one or more compounds of formula D-2.7. Medium according to claim 1 , characterized in that it comprises one or more polymerisable compounds.8. Method of stabilisation of a mesogenic medium characterized in that a medium according to is subjected to polymerisation of its polymerisable constituents.9. Mesogenic medium stabilised by the polymerisation of the polymerisable constituents of a medium according to .10. Light modulation element claim 1 , characterized in that it comprises a medium according to .11. Electro-optical display claim 1 , characterized in that it comprises a medium according to .12. (canceled) The present invention relates to compounds, media comprising these compounds and to electro-optical displays comprising these media as light modulation media. Preferably, the compounds of the present invention are mesogenic compounds and they are preferably used in liquid crystalline media. In particular the electro-optical displays according to the present invention are displays, which are operated at a temperature, at which the mesogenic modulation media are in an optically isotropic phase, preferably in a blue phase.Electro-optical displays and mesogenic light modulation media, which are in the isotropic phase when being operated in the display are described in DE 102 17 273 A. Electro-optical displays, and mesogenic light modulation media, which are in the optically isotropic blue phase, when being operated in the display are described in WO 2004/046 805.are mentioned as compounds for liquid crystalline compositions e.g. in US 2009/0256114 A1 and US/2011/0180756 A1.The mesogenic media and displays described in these references provide several significant advantages compared to well-known and ...

Подробнее
Номер записи: 48
25-04-2019 дата публикации

COMPOUNDS AND THE USE THEREOF IN METATHESIS REACTIONS

Номер: US20190119311A1
Автор: Frater Georg, Ondi Levente, TOTH Florian
Принадлежит:

The disclosure provides Group 6 complexes, which, in some embodiments, are useful for catalyzing olefin metathesis reactions. In some embodiments, the compounds are compounds of the following formula: 2. The compound of claim 1 , wherein Ris phenyl claim 1 , 2 claim 1 ,6-dichlorophenyl claim 1 , 2 claim 1 ,6-dimethylphenyl claim 1 , 2 claim 1 ,6-diisopropylphenyl claim 1 , 2-trifluoromethylphenyl claim 1 , pentafluorophenyl claim 1 , tert-butyl claim 1 , or 1-adamantyl.3. The compound of claim 1 , wherein Ris pyrrol-1-yl claim 1 , 2 claim 1 ,5-dimethylpyrrol-1-yl claim 1 , 2 claim 1 ,5-diphenylpyrrol-1-yl claim 1 , or indol-1-yl.5. The compound of claim 1 , wherein Ris methyloxy claim 1 , ethyloxy claim 1 , or isopropyloxy.6. The compound of claim 1 , wherein Rand Rare independently a hydrogen atom claim 1 , methyl claim 1 , a halogen atom claim 1 , or methyloxy.7. A method for carrying out a metathesis reaction claim 1 , the method comprising:providing a first compound having one or more carbon-carbon double bonds; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'reacting the first compound via a metathesis reaction in the presence of a compound of .'}8. The method of claim 7 , wherein the first compound has two or more carbon-carbon double bonds.9. The method of claim 8 , wherein the metathesis reaction is a ring-closing metathesis reaction between two of the two or more carbon-carbon double bonds of the first compound.10. A method of carrying out a metathesis reaction claim 8 , the method comprising:providing a first compound having one or more carbon-carbon double bond and a second compound having one or more carbon-carbon double bonds; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'reacting the first compound and the second compound via a metathesis reaction in the presence of a compound of .'}11. The method of claim 10 , wherein the first compound and the second compound are the same compound.12. The method of claim 10 , wherein the first compound ...

Подробнее
Номер записи: 49
16-04-2020 дата публикации

NEW ADIPATE-TYPE COMPOUNDS AND A PROCESS OF PREPARING IT

Номер: US20200115359A1
Автор: SØLVHØJ Amanda Birgitte, TAARNING Esben
Принадлежит: Haldor Topsoe A/S

New adipate-type compounds suitable as an intermediate in organic chemistry, a platform chemical for the production of other chemicals, and as a monomer and a co-monomer useful for the preparation of polymers and co-polymers. Also, a process of preparing the new adipate-type compounds from bio-based raw materials such as sugars. 2. The compound according to claim 1 , wherein n is 2.3. The compound according to claim 1 , wherein n is 3.5. The process according to claim 4 , wherein n is 2.6. The process according to claim 4 , wherein n is 3.7. The process according to claim 4 , wherein the conversion temperature of iii) is in the range of from 20 to 120° C.8. The process according to claim 4 , wherein step iii) is continued for a period of time in the range of from 5 minutes to 24 hours.9. The process according to claim 4 , wherein the conversion step of iii) is conducted at a pressure in the range of from 1 to 1000 kPa claim 4 , such as from 10 to 125 kPa.10. The process according to claim 4 , wherein the conversion step of iii) is conducted in the presence of a solvent selected from methyl lactate claim 4 , ethyl lactate claim 4 , toluene claim 4 , dichlormethane claim 4 , or mixtures thereof. The present application is a divisional of U.S. application Ser. No. 16/096,103, filed on Oct. 24, 2018, which is a U.S. National Stage of International Application No. PCT/EP2017/060702, filed on May 4, 2017, which claims the benefit of Danish Application No. PA 2016-00273, filed on May 4, 2016. The entire contents of each of U.S. application Ser. No. 16/096,103, International Application No. PCT/EP2017/060702, Danish Application No. PA 2016-00273 are hereby incorporated herein by reference in their entirety.The present invention regards a new compound suitable as an intermediate in organic chemistry, a platform chemical for the production of other chemicals, and as a monomer and co-monomer useful for the preparation of polymers and co-polymers. The invention also regards the ...

Подробнее
Номер записи: 50
16-04-2020 дата публикации

ENZYME-TRIGGERED CARBON MONOXIDE RELEASING MOLECULES

Номер: US20200115360A1
Автор: Ji Xingyue, Wang Binghe
Принадлежит:

The present invention generally relates to carbon monoxide releasing compounds and compositions, and their use as carbon monoxide prodrugs. The compounds disclosed herein contain a cyclopentadienone moiety, a non-reactive dienophile, and an enzyme-cleavable tethering moiety connecting the cyclopentadienone moiety to the non-reactive dienophile. Cleavage of the enzyme-cleavable tethering moiety results in conversion of the non-reactive dienophile to a reactive dienophile 1. A compound comprising a cyclopentadienone moiety , a non-reactive dienophile , and an enzyme-cleavable tethering moiety connecting the cyclopentadienone moiety to the non-reactive dienophile , wherein cleavage of the enzyme-cleavable tethering moiety results in conversion of the non-reactive dienophile to a reactive dienophile.3. The compound of claim 2 , or a pharmaceutically acceptable salt thereof claim 2 , wherein the moiety —X—Y— is —O—C(O)—.4. The compound of claim 2 , or a pharmaceutically acceptable salt thereof claim 2 , wherein Rand Rare taken together to form a fused tricyclic moiety.7. The compound of claim 2 , or a pharmaceutically acceptable salt thereof claim 2 , wherein{'sup': 1a', '1b', '1c, 'Ris selected from the group consisting of 3- to 8-membered heterocyclyl and —NRR,'}{'sup': '1b', 'sub': '1-8', 'Ris selected from H and Calkyl; and'}{'sup': '1c', 'sub': '1-8', 'Ris selected from H, Calkyl, and a solubilizing moiety.'}8. The compound of claim 7 , or a pharmaceutically acceptable salt thereof claim 7 , wherein the solubilizing moiety is selected from the group consisting of an oligo(ethylene glycol) claim 7 , a poly(ethylene glycol) claim 7 , and a monosaccharide.10. A pharmaceutical composition comprising a compound according to and a pharmaceutically acceptable excipient.11. A method for delivering carbon monoxide to a subject in need thereof claim 1 , the method comprising administering to the subject a compound according to .12. A method for treating a disease or condition ...

Подробнее
Номер записи: 51
11-05-2017 дата публикации

AMORPHOUS FORM OF ELIGLUSTAT HEMITARTARATE

Номер: US20170129869A1
Автор: PEDDY Vishweshwar, VELAGA Dharma Jagannadha Rao, VYALA Sunitha
Принадлежит:

The present application relates to the solid state forms of Eliglustat hemitartrate and the processes for the preparation thereof. The application further provides solid dispersion of Eliglustat hemitartrate having Eliglustat hemitartrate in amorphous form. 2: A process for preparing amorphous form of Eliglustat hemitartrate comprising:a) providing a solution of Eliglustat hemitartrate in a solvent;b) removing the solvent from the solution obtained in step a), andc) recovering amorphous form of Eliglustat hemitartrate.3: The process of wherein suitable solvent in step a) is selected from alcohols claim 2 , esters claim 2 , ketones claim 2 , hydrocarbons claim 2 , water or mixtures thereof.4: The process of wherein suitable solvent in step a) is selected from methanol claim 2 , isopropyl alcohol claim 2 , ethyl acetate claim 2 , acetone claim 2 , dichloromethane or mixtures thereof.5: The process of wherein removal of solvent in step b) is affected by evaporation claim 2 , freeze drying claim 2 , spray drying claim 2 , lyophilization claim 2 , by addition of suitable anti-solvent or any combination thereof.6: The process of wherein step c) involves an additional step of drying the isolated Eliglustat hemitartrate.7: A solid dispersion comprising amorphous Eliglustat hemitartrate in a dispersing agent.8: The solid dispersion of claim 7 , wherein the dispersing agent comprises hydroxypropyl methyl cellulose (HPMC) claim 7 , Polyvinyl pyrrolidone (PVP) claim 7 , Colloidal silicon dioxide and the like.9: The solid dispersion of claim 8 , wherein PVP is of different grades like K-15 claim 8 , K-30 claim 8 , K-60 and like.10: The solid dispersion of claim 8 , wherein colloidal silicon dioxide like Syloid 244 FP is employed.11: A pharmaceutical composition comprising solid dispersion of . The present application relates to the solid state forms of Eliglustat hemitartrate and the processes for the preparation thereof.Chemically Eliglustat is named N-[(1R,2R)-2-(2,3-dihydro-1 ...

Подробнее
Номер записи: 52
28-05-2015 дата публикации

Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof

Номер: US20150148539A1
Автор: Andrews Robert Carl, Behme Christopher, Bondlela Muralidhar, Christen Daniel P., Davis Stephen Thomas, Freeman Jennifer L.R., Gohimukkula Devi Reddy, Guzel Mustafa, JR. James C., Kalpathy Santhosh, Mjalli Adnan M.M., Polisetti Dharma Rao, Quada, Yarragunta Ravindra Reddy, Yokum Thomas Scott
Принадлежит:

The present invention relates to substituted azoanthracene derivatives and intermediates for the preparation thereof. The substituted azoanthracene derivatives and associated intermediates may be useful for the preparation of pharmaceutical compositions for the treatment or prevention of diseases, disorders, and conditions wherein modulation of the human GLP-1 receptor is beneficial. 2. The compound of claim 1 , wherein Ris —(R)-1-phenyl-propyl.3. The compound of claim 1 , wherein Ris —(S)-1-phenyl-propyl.6. The compound of claim 5 , wherein Ris —(R)-1-phenyl-propyl.7. The compound of claim 5 , wherein Ris —(S)-1-phenyl-propyl.9. The compound of claim 8 , wherein Ris —(R)-1-phenyl-propyl.10. The compound of claim 8 , wherein Ris —(S)-1-phenyl-propyl. 1. Field of InventionThe present invention relates to substituted azoanthracene derivatives and intermediates for the preparation thereof. The substituted azoanthracene derivatives and associated intermediates may be useful for the preparation of pharmaceutical compositions for the treatment or prevention of diseases, disorders, and conditions wherein modulation of the human GLP-1 receptor is beneficial.2. Description of Related ArtDiabetes mellitus type 2 is a metabolic disorder where the disease progression may be characterized by one or more of peripheral tissue insulin resistance, hyperglycemia, islet b-cell compensation, hyperinsulinemia, dyslipidemia, increased liver gluconeogenesis, and ultimate loss of b-cell mass and function. The pathophysiological consequences of aberrant glucose and lipid metabolism are toxicity to organs such as the kidney, eye, peripheral neurons, vasculature and heart. Thus, there is a need for agents that may delay disease progression by improving glycemic control and by improving b-cell mass and function.Glucagon-like peptide-1 (GLP-1) is a member of the incretin family of neuroendocrine peptide hormones secreted from L-cells of the intestine in response to food ingestion. GLP-1 has ...

Подробнее
Номер записи: 53
04-06-2015 дата публикации

METHOD OF PREPARING ESTER COMPOUND AND ESTER COMPOUND PREPARED THEREBY

Номер: US20150152036A1
Автор: Choe Yong-Jin, KONG Myungjin, Lee Won Jae
Принадлежит:

This invention relates to a method of preparing an ester compound, including adding carboxylic acid to a mixture of glycerol and acetone in the presence of a sulfuric acid catalyst and applying an ultrasonic wave to induce an esterification reaction, and to an ester compound prepared thereby. 1. A method of preparing an ester compound , comprising adding carboxylic acid to a mixture of glycerol and acetone in presence of a sulfuric acid catalyst and applying an ultrasonic wave to induce an esterification reaction.2. The method of claim 1 , wherein the carboxylic acid is formic acid.3. The method of claim 1 , wherein the method is a one-pot process.4. The method of claim 1 , wherein applying the ultrasonic wave is performed at a power density of 20˜700 W/cm.5. The method of claim 1 , wherein applying the ultrasonic wave is performed at a power density of 70˜500 W/cm.6. The method of claim 1 , wherein applying the ultrasonic wave is performed for 1˜400 min.7. The method of claim 1 , wherein applying the ultrasonic wave is performed for 5˜100 min.8. The method of claim 1 , wherein the acetone is added in an amount of 3˜15 equivalents based on the glycerol.9. The method of claim 1 , wherein the formic acid is added in an amount of 1˜5 equivalents based on the glycerol.10. The method of claim 1 , wherein the esterification reaction is carried out at −20˜10° C.11. The method of claim 1 , wherein the ester is prepared at a yield of 30% or more.12. The method of claim 1 , wherein the ester compound is any one or more selected from the group consisting of (2 claim 1 ,2-dimethyl-1 claim 1 ,3-dioxolan-4-yl)methyl formate claim 1 , 2 claim 1 ,2-dimethyl-1 claim 1 ,3-dioxan-5-yl formate claim 1 , glyceryl formate and 2-hydroxypropane-1 claim 1 ,3-diyl diformate.13. An ester compound prepared by the method of .14. The ester compound of claim 13 , wherein the ester compound is any one or more selected from the group consisting of (2 claim 13 ,2-dimethyl-1 claim 13 ,3-dioxolan-4-yl ...

Подробнее
Номер записи: 54
02-06-2016 дата публикации

LIQUID CRYSTAL COMPOUND HAVING 2, 6-DIFLUOROPHENYL ETHER STRUCTURE AND LIQUID CRYSTAL COMPOSITION THEREOF

Номер: US20160152589A1
Автор: Kusumoto Tetsuo, Tojo Kenta
Принадлежит: DIC CORPORATION

The present invention relates to a compound having 2,6-difluorophenyl ether structure and useful as an organic electronic material and a medicine/agrochemical, particularly a material for liquid crystal display devices, and also relates to an effective method for producing the same. The present invention provides a compound represented by general formula (1) 3. The compound according to claim 1 , wherein in the general formula (1) claim 1 , Z claim 1 , Z claim 1 , Z claim 1 , and Zeach independently represent —OCF— claim 1 , —CFO— claim 1 , —CHCH— claim 1 , —C≡C— claim 1 , or a single bond.4. The compound according to claim 1 , wherein in the general formula (I) W represents a fluorine atom a cyano group claim 1 , or —OCF.8. A liquid crystal composition comprising one or two or more compounds according to .9. A liquid crystal display device using the liquid crystal composition according to . The present invention relates to a compound having a 2,6-difluorophenyl ether structure useful as an organic electronic material and a medicine/agrochemical, particularly a material for liquid crystal display devices, and also relates to an effective, method for producing the same.Liquid crystal display devices have been used for watches and electronic calculators, various measuring apparatuses, automotive panels, word processors, electronic notebooks, printers, computers, televisions, watches, advertising displays, etc. Typical examples of a liquid crystal display mode include a TN (twisted nematic) mode, a STN (super twisted nematic) mode, a vertical alignment mode using TFT (thin-film transistor), an IPS (in-plane switching) mode, and the like. Liquid crystal compositions used for these liquid crystal display devices are required to have stability to external factors such as moisture, air, heat, light, and the like, exhibit a liquid crystal phase (a nematic phase, a smectic phase, a blue, phase, and the like) within as wide a temperature range as possible including room ...

Подробнее
Номер записи: 55
02-06-2016 дата публикации

SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN

Номер: US20160154304A1
Автор: ANRYU Yukako, ICHIKAWA Koji, OCHIAI Mitsuyoshi
Принадлежит: Sumitomo Chemical Company, Limited

A salt represented by formula (I): 2. The salt according to claim 1 , wherein Xis *—CO—O—.3. The salt according to claim 1 , wherein Ris an adamantyl group.4. An acid generator claim 1 , which comprises the salt according to .5. A resist composition comprising the salt according to and a resin having an acid-labile group.6. The resist composition according to claim 5 , further comprising a salt which generates an acid weaker in acidity than an acid generated from the acid generator.7. A method for producing a resist pattern comprising steps (1) to (5);{'claim-ref': {'@idref': 'CLM-00005', 'claim 5'}, '(1) applying the resist composition according to onto a substrate;'}(2) drying the applied composition to form a composition layer;(3) exposing the composition layer;(4) heating the exposed composition layer; and(5) developing the heated composition layer. This application claims priority to Japanese Application No. 2014-241765 filed on Nov. 28, 2014. The entire disclosures of Japanese Application No. 2014-241765 is incorporated hereinto by reference.1. Field of the InventionThe disclosure relates to a salt, an acid generator, a resist composition and a method for producing resist pattern.2. Related ArtA resist composition which contains an acid generator including a salt represented by the following formula is described in Patent document of JP 2008-069146A.The present disclosure provides following inventions of <1> to <7>.<1> A salt represented by formula (I):wherein Qand Qeach independently represent a fluorine atom or a Cto Cperfluoroalkyl group,Rand Reach independently represent a hydrogen atom, a fluorine atom or a Cto Cperfluoroalkyl group,z represents an integer of 0 to 6,Xrepresents *—O—, *—CO—O— or *—O—CO—,* represents a binding site to CRRor CQQ,Lrepresents a Cto Calkanediyl group,Rrepresents a Cto Calicyclic hydrocarbon group in which a hydrogen atom may be replaced by a hydroxy group, and in which a methylene group may be replaced by an oxygen atom or a ...

Подробнее
Номер записи: 56
16-05-2019 дата публикации

NEW ADIPATE-TYPE COMPOUNDS AND A PROCESS OF PREPARING IT

Номер: US20190144415A1
Автор: SØLVHØJ Amanda Birgitte, TAARNING Esben
Принадлежит: Haldor Topsoe A/S

The present invention regards new adipate-type compounds suitable as an intermediate in organic chemistry, a platform chemical for the production of other chemicals, and as a monomer and co-monomer useful for the preparation of polymers and copolymers. The invention also regards the process of preparing the new adipate-type compounds from bio-based raw materials such as sugars.

Подробнее
Номер записи: 57
11-06-2015 дата публикации

Prodrugs of Substituted 1,3-Dioxanes and Their Uses

Номер: US20150158838A1
Автор: Alberts Peteris, Sorensen Alexandra Santana
Принадлежит: EVOLVA SA

The present invention relates to prodrugs of compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The prodrugs of the compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer. 29-. (canceled)1115-. (canceled)16. A method for treating or preventing a disorder associated with a thromboxane A2 or peroxisome proliferator-activated receptors claim 1 , the method comprising: administering to a subject an effective amount of a compound of or acceptable salts claim 1 , N-oxides claim 1 , hydrates claim 1 , or solvates thereof; and pharmaceutically-acceptable carrier or diluent.17. The method of claim 16 , wherein the disorder is selected from the group consisting of diabetes claim 16 , cancer claim 16 , inflammation claim 16 , AIDS claim 16 , metabolic syndrome claim 16 , obesity claim 16 , pre-diabetes claim 16 , hypertension and dyslipidemia.18. The method of claim 17 , wherein the subject is a human.1923-. (canceled)24. The method of claim 16 , wherein the disorder is selected from the group consisting of myocardial infarction claim 16 , thrombosis claim 16 , thrombotic disorders claim 16 , pulmonary hypertension claim 16 , atherosclerosis claim 16 , diabetic nephropathy claim 16 , retinopathy claim 16 , peripheral arterial disease claim 16 , lower limb circulation claim 16 , pulmonary embolism claim 16 , thrombus formation claim 16 , stent-triggered thrombus formation claim 16 , stent-triggered hyperplasia claim 16 , septic shock claim 16 , preeclampsia claim 16 , asthma claim 16 , allergic rhinitis claim 16 , tumour angiogenesis and metastasis.25. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.26. (canceled)27. The composition according to claim 25 , wherein the ...

Подробнее
Номер записи: 58
09-06-2016 дата публикации

LIQUID CRYSTAL COMPOUND HAVING 2, 6-DIFLUOROPHENYLETHER STRUCTURE, AND LIQUID CRYSTAL COMPOSITION CONTAINING THE SAME

Номер: US20160159765A1
Автор: Kusumoto Tetsuo, Tojo Kenta
Принадлежит: DIC CORPORATION

The present invention relates to a compound having a 2,6-difluorophenylether structure useful as organic electronic materials, pharmaceuticals and agrochemicals, and in particular, liquid crystal display device materials. 19-. (canceled)12. The compound according to claim 10 , wherein Z claim 10 , Z claim 10 , Z claim 10 , Z claim 10 , and Zin general formula (1) each independently represent —OCH— claim 10 , —CFO— claim 10 , —CHCH— claim 10 , —C≡C— claim 10 , or a single bond.13. The compound according to claim 10 , wherein W in general formula (1) represents a fluorine atom claim 10 , a cyano group claim 10 , or —OCF.17. A liquid crystal composition comprising one or more compounds according to .18. A liquid crystal display device that uses the liquid crystal composition according to . The present invention relates to a compound having a 2,6-difluorophenylether structure useful as organic electronic materials, pharmaceuticals and agrochemicals, and in particular, liquid crystal display device materials.Liquid crystal display devices are being used in watches, calculators, various measurement instruments, automobile panels, word processors, electronic organizers, printers, computers, televisions, clocks, advertising boards, etc. Representative examples of liquid crystal display modes are twisted nematic (TN) mode, super twisted nematic (STN) mode, and vertical alignment (VA) or in-plane-switching (IPS) mode that uses thin film transistors (TFTs). The liquid crystal compositions used in these liquid crystal display devices are required to be stable against external factors such as moisture, air, heat, and light, exhibit a liquid crystal phase (nematic phase, smectic phase, or blue phase, for example) in a temperature range as wide as possible around room temperature, have low viscosity, and operate at low drive voltage. The liquid crystal compositions are composed of several to dozens of compounds in order to optimize dielectric anisotropy (Δ∈), refractive index ...

Подробнее
Номер записи: 59
24-06-2021 дата публикации

Compound, mixture, liquid crystal composition, cured product, optically anisotropic body, and reflective film

Номер: US20210189243A1
Автор: Keisuke KODAMA, Shunya Katoh, Yuko Suzuki
Принадлежит: Fujifilm Corp

An object of the present invention is to provide a compound which increases the intensity of HTP by exposure to irradiation with light such as ultraviolet rays, and a mixture including the compound. Another object of the present invention is to provide a liquid crystal composition, a cured product, an optically anisotropic body, and a reflective film.The compound of the present invention is represented by General Formula (1).

Подробнее
Номер записи: 60
16-06-2016 дата публикации

IRE-1alpha Inhibitors

Номер: US20160168116A1
Автор: Flynn Gary A., Lonergan David G., PALLAI Peter V., Patterson John B., Zeng Qingpeng
Принадлежит:

Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies. 14. The compound or the pharmaceutically acceptable salt thereof of claim 11 , wherein Ris selected from the group consisting of hydrogen claim 11 , —F claim 11 , —CF claim 11 , —NO claim 11 , and —OCH.20. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The invention relates to IRE-1α inhibitors and their therapeutic uses.Protein folding stress in the endoplasmic reticulum of a cell initiates a signal transduction cascade termed the unfolded protein response or UPR. A key enzyme, inositol requiring enzyme 1 (IRE-1α), relieves protein folding stress by enhancing molecular chaperone activity and therefore protects cells from stress induced apoptosis. Inhibitors of IRE-1α are useful for treating at least B cell autoimmune diseases, certain cancers, and some viral infections.The invention provides IRE-1α inhibitor compounds and prodrugs and pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions and methods of using the IRE-1α inhibitor compounds, prodrugs, and pharmaceutically acceptable salts thereof therapeutically to treat disorders associated with the unfolded protein response. Patients who can be treated include those with B cell autoimmune diseases, certain cancers, and some viral infections.The present invention comprises numerous chemical compounds related by structure and by function, as well as methods for their use. Various groupings of these compounds comprising from one to any number of them, and their uses, can be defined and constitute individual embodiments of the invention. Some embodiments will specifically include certain compounds ...

Подробнее
Номер записи: 61
25-06-2015 дата публикации

KETAL AMIDE COMPOUNDS, METHODS OF MAKING, AND APPLICATIONS

Номер: US20150175568A1
Автор: GOETZ Adam E., SCHOLTEN Marc D., SELIFONOV Sergey, ZHOU Ning
Принадлежит:

Disclosed herein are ketal amide compounds. The ketal amide compounds are synthesized by the reaction of ketal acids or ketal esters with amine functional compounds. Also disclosed are methodologies useful to make the ketal amide compounds. Also disclosed herein are formulations and articles containing the ketal amide compounds. 2. The compound of wherein the one or more heteroatoms are independently halogen claim 1 , nitrogen claim 1 , oxygen claim 1 , sulfur claim 1 , silicon claim 1 , or phosphorus.3. The compound of wherein the one or more heteroatoms are in a functional group that is amino claim 2 , carbonate claim 2 , imide claim 2 , amide claim 2 , sulfone claim 2 , sulfonamide claim 2 , urethane claim 2 , mercapto claim 2 , disulfide claim 2 , ether claim 2 , ester claim 2 , phosphate claim 2 , phosphonooxy claim 2 , silane claim 2 , or silyl functional groups claim 2 , or a combination thereof.4. The compound of wherein the polymeric group comprises a surface claim 1 , a layer on top of a surface claim 1 , a particle surface claim 1 , or a porous particle interior.5. The compound of wherein α is 2 and Ris —(CH)— claim 1 , 1 claim 1 ,2-cyclohexyl claim 1 , —(CH)— claim 1 , —CHCHCH(CH)CHC(CH)CH— claim 1 , or —CHCHC(CH)CHCH(CH)CH—.6. The compound of wherein all values of a are 0 claim 1 , 1 claim 1 , or 2.7. The compound of wherein all values of a are 2 and all Rand Rare hydrogen.8. The compound of wherein all Rare methyl.9. The compound of wherein all b are 0 and all Rand Rare hydrogen.10. The compound of wherein all b are 1 claim 1 , all Rare —CHOH claim 1 , all Rare CHCHor CH claim 1 , and all R claim 1 , Rare H.11. The compound of wherein Ris —CH—OH12. The compound of wherein α is 2.15. The compound of wherein the A groups comprise a mixture of saturated and unsaturated fatty acid ester groups.16. A formulation comprising the compound of .17. The formulation of wherein the compound of is a plasticizer claim 1 , a coalescing solvent claim 1 , a cosolvent ...

Подробнее
Номер записи: 62
01-07-2021 дата публикации

COMPOUND, COMPOSITION, CURED PRODUCT, OPTICALLY ANISOTROPIC BODY, AND REFLECTIVE FILM

Номер: US20210198230A1
Автор: KATOH Shunya, KODAMA Keisuke, Suzuki Yuko
Принадлежит: FUJIFILM Corporation

The present invention provides a compound having an excellent rate of change in HTP due to exposure. The present invention further provides a composition formed of the compound, a cured product, an optically anisotropic body, and a reflective film. 2. The compound according to claim 1 ,{'sup': '1', 'wherein Arepresents an aromatic hydrocarbon ring group or an aromatic heterocyclic group.'}3. The compound according to claim 1 ,{'sup': 1', '2, 'wherein Xand Xare bonded to each other to form a ring.'}4. The compound according to claim 1 ,{'sup': 1', '3', '5, 'wherein at least one of X, X, or Xrepresents the group represented by General Formula (2), and'}{'sup': 2', '4', '6, 'at least one of X, X, or Xrepresents the group represented by General Formula (2).'}5. The compound according to claim 1 ,{'sup': 3', '4', '5', '6, 'wherein at least one of X, X, X, or Xrepresents the group represented by General Formula (2), and'}{'sup': 1', '2, 'claim-text': {'br': None, 'sup': 3', '4', '2, 'sub': 'k', 'R-(A-Z)—*\u2003\u2003(A)'}, 'at least one of Xor Xrepresents a group represented General Formula (A),'}{'sup': 3', '2', '4, 'sub': 2', '2', '2', '2', '2', '2', '2', '2', '2', '2, 'in General Formula (A), k represents an integer of 2 or more, Rrepresents a hydrogen atom or a substituent, Zrepresents a single bond, —O—, —S—, —CHO—, —CO—, —COO—, —CO—S—, —O—CO—O—, —CO—NH—, —CHS—, —CFO—, —CFS—, —CH═CH—COO—, —CH═CH—OCO—, —OCO—C(CN)═CH—, —COO—CHCH—, —OCO—CHCH—, —COO—CH—, —OCO—CH—, —CH═CH—, —N═N—, —CH═N—N═CH—, —CF═CF—, or —C═C—, Arepresents a hydrocarbon ring group or a heterocyclic group, and * represents a bonding position to the fused ring in General Formula (1).'}6. The compound according to claim 1 , {'br': None, 'sup': 2', '3', '1', '2', 'x, 'sub': 'm', 'R-(A-Z)-ACO—CH═CH—*\u2003\u2003(3)'}, 'wherein the group represented by General Formula (2) is a group represented by General Formula (3),'}{'sup': 2', '1', '2', '3', 'x', '2, 'sub': 2', '2', '2', '2', '2', '2', '2', '2', '2', '2, ' ...

Подробнее
Номер записи: 63
22-06-2017 дата публикации

NOVEL ORGANOLEPTIC COMPOUNDS AND THEIR USE IN FLAVOR AND FRAGRANCE COMPOSITIONS

Номер: US20170174650A1
Автор: AGYEMANG David O., Cai Tingwei, CANNON Robert J., Chen Zhen, CURTO Nicole L., JANCZUK Adam Jan, Jones Paul D., KAZIMIERSKI Arkadiusz, LI Jing, Rodriguez David, VAN KIPPERSLUIS BRAIN Anja
Принадлежит:

The present invention is directed to novel organoleptic compounds, a process of augmenting, enhancing or imparting taste to a material selected from the group consisting of a foodstuff, a chewing gum, a dental product, an oral hygiene product and a medicinal product comprising the step of incorporating an olfactory acceptable amount of such novel organoleptic compounds, and a process of improving, enhancing or modifying a fragrance composition through the addition of an olfactory acceptable amount of such novel organoleptic compounds. 6. The compound of selected from the group consisting of:3-mercapto-3,7-dimethyl-oct-6-en-1-ol;3-mercapto-3,7-dimethyl-oct-6-enal;S-[1-(2-hydroxy-ethyl)-1,5-dimethyl-hex-4-enyl]-thioacetate; and3-acetylsulfanyl-3,7-dimethyl-oct-6-enyl acetate.7. A flavor composition comprising an olfactory acceptable amount of the compound of any of the preceding claims.8. The flavor composition of further comprising a material selected from the group consisting of a foodstuff claim 7 , a chewing gum claim 7 , a dental product claim 7 , an oral hygiene product and a medicinal product.9. The flavor composition of claim 7 , wherein the olfactory acceptable amount is from about 1 part per billion to about 1000 parts per million by weight.10. The flavor composition of claim 7 , wherein the olfactory acceptable amount is from about 10 parts per billion to about 100 parts per million by weight.11. The flavor composition of claim 7 , wherein the olfactory acceptable amount is from about 100 parts per billion to about 10 parts per million by weight.12. A method of improving claim 7 , enhancing or modifying a flavor composition through the addition of an olfactory acceptable amount of the compound of any of the preceding claims.13. A fragrance composition comprising an olfactory acceptable amount of the compound of any of the preceding claims.14. The fragrance composition of further comprising a material selected from the group consisting of a polymer and a non ...

Подробнее
Номер записи: 64
02-07-2015 дата публикации

SYNTHETIC METHODS AND COMPOUNDS RELATED THERETO

Номер: US20150184206A1
Автор: Dai Zhipeng, Green Thomas K.
Принадлежит:

Disclosed herein are synthetic methods and compounds related to the compounds that are useful as or in the production of biologically active compounds. Stereoselective and stereospecific synthetic methods are disclosed to produce compounds, such as, for example, γ,δ-unsaturated-β-hydroxyesters and aminated derivatives thereof, at high yields with desired stereochemistry. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. 2. The synthetic method of claim 1 , wherein Ris hydrogen and Ris selected from aryl claim 1 , cycloalkyl claim 1 , cycloalkenyl claim 1 , heterocyclyl claim 1 , heteroaryl claim 1 , -alkyl-aryl claim 1 , -alkenyl-aryl claim 1 , alkynyl-aryl claim 1 , -alkyl-cycloalkyl claim 1 , -alkenyl-cycloalkyl claim 1 , alkynyl-cycloalkyl claim 1 , alkyl-heterocyclyl claim 1 , -alkenyl-heterocyclyl claim 1 , alkynyl-heterocyclyl claim 1 , -alkyl-heteroaryl claim 1 , -alkenyl-heteroaryl claim 1 , alkynyl-heteroaryl claim 1 , alkyl claim 1 , alkenyl claim 1 , alkynyl claim 1 , and haloalkyl.3. The synthetic method of claim 1 , wherein Ris hydrogen.4. The synthetic method of claim 1 , wherein Ris selected from alkyl claim 1 , alkenyl claim 1 , and alkynyl.5. The synthetic method of claim 1 , wherein the ketoreductase is selected from 130 claim 1 , NADH-101 claim 1 , P3-G09 claim 1 , and P3-H12.9. The synthetic method of claim 8 , wherein the ester of the third compound is reduced to form an alcohol in a fourth compound.11. The synthetic method of claim 10 , wherein the method further comprises cleaving the N—N bond in the fifth compound claim 10 , thereby forming a sixth compound.15. The synthetic method of claim 13 , wherein the ester of the third compound is reduced to form an alcohol in a fourth compound.18. The synthetic method of claim 17 , wherein the method further comprises cleaving the N—N bond in the fifth compound claim 17 , thereby forming a sixth ...

Подробнее
Номер записи: 65
18-09-2014 дата публикации

MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20140275171A1
Автор: Boebel Timothy, Bravo-Altamirano Karla, Graupner Paul, Heemstra Ronald J., Herrick Jessica, JR. Kevin G., Li Fangzheng, Meyer, Nugent Benjamin, Owen W. John, Renga James M., Wang Nick X., Yao Chenglin
Принадлежит:

The invention relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. A compound according to claim 1 , wherein:{'sub': '6', 'wherein, R is H, or C(O)R;'}{'sub': 1', '6, 'Ris C(O)R;'}{'sub': 2', '5, 'Ris independently or separately H, alkyl, alkenyl, aryl, each substituted with 0, 1 or multiple R;'}{'sub': '3', 'Ris independently or separately H, methyl;'}{'sub': '5', 'Ris alkyl, alkoxy, halo, haloalkyl, or aryl; and'}{'sub': '6', 'Ris alkoxy, or benzyloxy.'}5Mycosphaerella graminicolaSeptoria triticiPuccinia triticinaPuccinia striiformisVenturia inaequalisUstilago maydisUncinula necatorRhynchosporium secalisMagnaporthe griseaPseudoperonospora cubensisPhakopsora pachyrhiziLeptosphaeria nodorumBlumeria graministriticiBlumeria graminishordeiErysiphe cichoracearumGlomerella lagenariumCercospora beticolaAlternaria solaniPyrenophora teres. The compositions according to claim 4 , wherein the plant pathogen is least one pathogen selected from the group consisting of: Leaf Blotch of Wheat ( claim 4 , anamorph: ) claim 4 , Wheat Brown Rust () claim 4 , Stripe Rust () claim 4 , Scab of Apple () claim 4 , Blister Smut of Maize () claim 4 , Powdery Mildew of Grapevine () claim 4 , Barley scald () claim 4 , Blast of Rice () claim 4 , Downy Mildew of Cucurbits () claim 4 , Rust of Soybean () claim 4 , Glume Blotch of Wheat () claim 4 , Powdery Mildew of Wheat (f. sp. ) claim 4 , Powdery Mildew of Barley (f. sp. ) claim 4 , Powdery Mildew of Cucurbits () claim 4 , Anthracnose of Cucurbits () claim 4 , Leaf Spot of Beet () claim 4 , Early Blight of Tomato () claim 4 , and Net Blotch of Barley ().6Septoria triticiPuccinia triticinaPhakopsora pachyrhizi. The composition according to claim 5 , wherein the fungal pathogen is at least one of Leaf Blotch of Wheat () claim 5 , Wheat Brown Rust () claim 5 , and Rust of Soybean ().8. The method according to claim 7 , wherein the compound is applied in a mixture with at least one additional compound selected from ...

Подробнее
Номер записи: 66
18-09-2014 дата публикации

PROCESS FOR THE PREPARATION OF (2,3-DIHYDRO-BENZO[B][1,4]DIOXIN-2-YL) METHANOL DERIVATIVES

Номер: US20140275576A1
Автор: Zinser Hartmut B.
Принадлежит: Janssen Pharmaceutica NV

The present invention is directed to a process for the preparation of (2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanol derivatives. 6. A process as in claim 5 , wherein —C(O)—Ris acyl; and wherein the acyl is selected from the group consisting of acetyl claim 5 , pivaloyl and benzoyl.7. A process as in claim 6 , wherein the acyl is benzoyl.8. A process as in claim 5 , wherein the compound of formula (VI-S) is present in an amount in the range of from about 1.0 to about 1.5 molar equivalents.9. A process as in claim 8 , wherein the compound of formula (VI-S) is present in an amount in the range of from about 1.1 to about 1.2 molar equivalents.10. A process as in claim 5 , wherein the base is selected from the group consisting of DBU claim 5 , KOtBu claim 5 , LiOtBu claim 5 , NaOCHand CsCO.11. A process as in claim 10 , wherein the base is selected from the group consisting of DBU claim 10 , KOtB and LiOtBu.12. A process as in claim 11 , wherein the base is KOtBu.13. A process as in claim 5 , wherein the base is present in an amount in the range of from about 1.0 to about 3.0 molar equivalents.14. A process as in claim 12 , wherein the base is present in an amount in the range of from about 2.1 to about 2.5 molar equivalents.15. A process as in claim 5 , wherein the mixture of the compound of formula (V-S) and the compound of formula (VI-S) is reacted at a temperature in the range of from about −25° C.16. A process as in claim 5 , wherein the compound of formula (IX) is selected from the group consisting of (R)-glycidyl-3-nitrobenzenesulfonate claim 5 , (R)-glycidyl-4-nitrobenzenesulfonate and (R)-glycidyl-4-tolylsulfonate.17. A process as in claim 16 , wherein the compound of formula (IX) is (R)-glycidyl-3-nitrobenzensulfonate.18. A process as in claim 5 , wherein the compound of formula (IX) is present in an amount in the range of from about 0.2 to about 3.0 molar equivalents.19. A process as in claim 18 , wherein the compound of formula (IX) is present in an amount of ...

Подробнее
Номер записи: 67
07-07-2016 дата публикации

CYCLIC OLEFIN COMPOUND HAVING PHOTOREACTIVE GROUP AND PHOTOREACTIVE POLYMER

Номер: US20160194418A1
Автор: Choi Dai Seung, Chun Sung-Ho, Park Eun Seok
Принадлежит:

There are provided a novel cyclic olefin compound having a photoreactive group and a photoreactive polymer. The cyclic olefin compound is applicable to various photoreactions, such as of liquid crystal alignment layers and can be preferably used as a precursor of various organic compounds or polymers. 3. The cyclic olefin compound of claim 2 , wherein each functional group of R5 to R8 is unsubstituted or substituted with a functional group selected from the group consisting of halogen claim 2 , alkyl claim 2 , alkenyl claim 2 , alkynyl claim 2 , haloalkyl claim 2 , haloalkenyl claim 2 , haloalkynyl claim 2 , aryl claim 2 , haloaryl claim 2 , arylalkyl claim 2 , haloarylalkyl claim 2 , alkoxy claim 2 , haloalkoxy claim 2 , carbonyloxy claim 2 , halocarbonyloxy claim 2 , aryloxy claim 2 , haloaryloxy claim 2 , silyl claim 2 , and siloxy.5. The photoreactive polymer of claim 4 , wherein the photoreactive polymer has a weight average molecular weight of 10 claim 4 ,000 to 1 claim 4 ,000 claim 4 ,000 g/mol.9. The preparation method of a photoreactive polymer of claim 8 , wherein in the performing of the ring-opening polymerization reaction claim 8 , a hydrogenation reaction is performed on a double bond in a norbornene ring claim 8 , such that the ring-opening and polymerization are performed.10. An alignment layer comprising the photoreactive polymer of .11. A liquid crystal retardation film comprising the alignment layer of and a liquid crystal layer on the alignment layer.12. A display device comprising the alignment layer of . The present invention relates to a novel cyclic olefin compound having a photoreactive group and a photoreactive polymer.More particularly, the present invention relates to a novel cyclic olefin compound having a photoreactive group and a photoreactive polymer prepared from the same that are applicable to various photoreactions, such as of liquid crystal alignment layers, or the like, and can also be preferably used as precursors of different ...

Подробнее
Номер записи: 68
06-07-2017 дата публикации

PREPARATION METHOD FOR CHIRAL INTERMEDIATE FOR USE IN STATINS

Номер: US20170190684A1
Автор: Chen Chaoyong, GUO Lina, HONG Hao, LI Jiuyuan, SHEN Litao, Tian Hongying
Принадлежит:

The present invention relates to a preparation method for a chiral intermediate for use in statins, acquired with chloroacetic acid and benzyl alcohol as starting materials via a series of reactions, namely etherification, condensation, substitution, and asymmetric reduction. The preparation method provided in the present invention has a novel route of synthesis, allows an intermediate compound to be introduced conveniently into the chiral center of a glycol via enzyme reduction, and not only is low in costs, but also is reliable in quality. The route of synthesis provided in the present invention uses raw materials of low costs, has an easy to operate process, and provides a final product of great purity and high yield. 2. The preparation method according to claim 1 , wherein R represents tert-butyl claim 1 , tert-pentyl claim 1 , cyclopentyl or cyclohexyl.4. The preparation method according to claim 1 , wherein the asymmetric reduction in step 4) comprises: evenly dispersing the diketone intermediate of formula (6) in a solvent claim 1 , adding a reductase claim 1 , formic acid or a formate salt and NAD claim 1 , adjusting pH value to 6.2˜6.4 claim 1 , then warming the system up to 27˜33° C. claim 1 , and maintaining the temperature for 17˜24 h.5. The preparation method according to claim 4 , wherein the mass ratio of the reductase to the diketone intermediate of formula (6) is 0.00005˜0.004:1.7. The preparation method according to claim 6 , wherein the diketoreductase mutant comprises an amino acid sequence shown in SEQ ID NO: 1 claim 6 , 2 claim 6 , 3 claim 6 , 4 claim 6 , 5 or 6.8. The preparation method according to claim 4 , wherein the solvent is one or more selected from the group consisting of purified water claim 4 , polyethylene glycol claim 4 , isopropanol claim 4 , acetonitrile claim 4 , tetrahydrofuran claim 4 , ethanol claim 4 , n-heptane claim 4 , toluene claim 4 , acetone claim 4 , dimethylformamide and methanol.9. The preparation method according ...

Подробнее
Номер записи: 69
06-07-2017 дата публикации

CLARIFYING AGENT COMPOSITION AND POLYOLEFIN COMPOSITION COMPRISING THE SAME

Номер: US20170190872A1
Автор: Mehl Nathan A.
Принадлежит:

An additive composition comprises 1,3:2,4-bis-O-[(3,4-dichlorophenyl)methylene]-D-glucitol and a low amount of residual acid. A polyolefin composition comprises a polyolefin polymer and the additive composition described above. 1. An additive composition comprising 1 ,3:2 ,4-bis-O-[(3 ,4-dichlorophenyl)methylene]-D-glucitol , wherein the additive composition comprises less than 0.052 mol. % of acid based on the amount of 1 ,3:2 ,4-bis-O-[(3 ,4-dichlorophenyl)methylene]-D-glucitol present in the additive composition.2. The additive composition of claim 1 , wherein the additive composition comprises about 0.05 mol. % or less of acid based on the amount of 1 claim 1 ,3:2 claim 1 ,4-bis-O-[(3 claim 1 ,4-dichlorophenyl)methylene]-D-glucitol present in the additive composition.3. The additive composition of claim 1 , wherein the additive composition comprises about 0.0475 mol. % or less of acid based on the amount of 1 claim 1 ,3:2 claim 1 ,4-bis-O-[(3 claim 1 ,4-dichlorophenyl)methylene]-D-glucitol present in the additive composition.4. The additive composition of claim 1 , wherein the additive composition comprises about 0.045 mol. % or less of acid based on the amount of 1 claim 1 ,3:2 claim 1 ,4-bis-O-[(3 claim 1 ,4-dichlorophenyl)methylene]-D-glucitol present in the additive composition.5. The additive composition of claim 1 , wherein the acid is selected from the group consisting of p-toluenesulfonic acid claim 1 , methanesulfonic acid claim 1 , sulfuric acid claim 1 , phosphoric acid claim 1 , hydrochloric acid claim 1 , hypophosphorous acid claim 1 , trifluoroacetic acid claim 1 , triflic acid claim 1 , and mixtures thereof.6. The additive composition of claim 1 , wherein the composition further comprises 1 claim 1 ,3:2 claim 1 ,4-bis-O-[(3 claim 1 ,4-dimethylphenyl)methylene]-D-glucitol.7. The additive composition of claim 6 , wherein the ratio of the mass of 1 claim 6 ,3:2 claim 6 ,4-bis-O-[(3 claim 6 ,4-dimethylphenyl)methylene]-D-glucitol present in the ...

Подробнее
Номер записи: 70
22-07-2021 дата публикации

LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND PHOTOELECTRIC DISPLAY DEVICE THEREOF

Номер: US20210222066A1
Автор: Han Wenming, He Di, Xu Haibin, Zhang Wenqi
Принадлежит: Jiangsu Hecheng Display Technology Co., Ltd.

A liquid crystal composition includes the compound of general formula I, and a photoelectric display device also includes the liquid crystal composition of general formula I. The compound of general formula I enables the liquid crystal composition including the same to maintain larger dielectric anisotropy, have a desired level of optical anisotropy, higher photo-thermal stability and nematic phase stability, and have a wide range of applicabilities, especially applicable to the IPS-type and TN-TFT-type liquid crystal display devices. 2. The compound according to claim 1 , wherein X represents —F claim 1 , —CFor —OCF.4. A liquid crystal composition claim 1 , comprising at least one compound of general formula I according to .5. The liquid crystal composition according to claim 4 , wherein the liquid crystal composition comprises at least one compound of general formula I-3 which provides 1-50% of the total weight of the liquid crystal composition.7. The liquid crystal composition according to claim 6 , wherein the liquid crystal composition comprises at least one compound of general formula II-1 which provides 10-85% of the total weight of the liquid crystal composition.8. The liquid crystal composition according to claim 7 , wherein the compound of general formula II-1 provides 15-55% of the total weight of the liquid crystal composition.9. The liquid crystal composition according to claim 8 , wherein the compound of general formula II-1 provides 25-50% of the total weight of the liquid crystal composition.10. The liquid crystal composition according to claim 5 , wherein the compound of general formula I-3 provides 2-25% of the total weight of the liquid crystal composition.11. A photoelectric display device comprising the liquid crystal composition according to . This application is the National Stage of International Application No. PCT/CN2018/120225, filed Dec. 11, 2018, which claims the benefit of Chinese Application No. 201711395076.9, filed Dec. 21, 2017, the ...

Подробнее
Номер записи: 71
25-09-2014 дата публикации

Method for Recovering Di-Trimethylolpropane and Trimethylolpropane-Enriched Product Streams From the Side Streams of Trimethylolpropane Production

Номер: US20140288318A1
Автор: Bermann Dirk, Frey Guido D., Nowotney Norman, Raff Donald K., Schalapski Kurt, Strutz Heinz
Принадлежит: OXEA GMBH

Process for obtaining ditrimethylolpropane and trimethylolpropane-enriched product streams from the high-boiling fractions and residues which are obtained in the distillative purification of trimethylolpropane includes three stage distillation characterized in that second and third stages are configured as thin film evaporators with a column attachment with the second stage facilitating trimethylopropane recovery and the third stage facilitating ditrimethylolpropane recovery. 1. Process for obtaining ditrimethylolpropane and trimethylolpropane-enriched product streams from the high-boiling fractions and residues which are obtained in the distillative purification of trimethylolpropane , characterized in that:(a) these high-boiling fractions and residues are combined and a polar solvent is added to produce a solution;(b) the solution produced according to step a) is treated at a temperature of 160 to 280° C. and at a pressure of 1 to 30 MPa with hydrogen in the presence of a catalyst and of an acidic compound;(c) the solution obtained according to step b) is removed from the catalyst and further solids, if present;(d) the solution obtained according to step c) is separated in a first distillation unit into a tops fraction comprising the polar solvent and low boilers and into a bottoms fraction with a content of the polar solvent up to 5000 ppm by weight, based on the bottoms fraction;(e) the bottoms fraction obtained according to step d) is supplied to a second distillation unit with at least 5 theoretical plates, said unit being configured as a thin-film evaporator with a column attachment, and a trimethylolpropane-enriched tops fraction is drawn off and a bottoms fraction is withdrawn; and(f) the bottoms fraction obtained according to step e) is supplied to a third distillation unit with at least 4 theoretical plates, said unit being configured as a thin-film evaporator with a column attachment, in which ditrimethylolpropane is obtained as the tops fraction and ...

Подробнее
Номер записи: 72
09-10-2014 дата публикации

STILBENOID COMPOUND AS INHIBITOR FOR SQUAMOUS CARCINOMA AND HEPATOMA AND USES THEREOF

Номер: US20140303241A1
Автор: CHANG Ling-Chu, CHEN Huei-Wen, Cheng Yung-Yi, HSIEH Min-Tsang, HUANG Li-Jiau, HUNG Hsin-Yi, KUO Sheng-Chu, Lee Kuo-Hsiung, Lin Hui-Yi, Liu Chin-Yu, WAY Tzong-Der, WU Tian-Shung, YANG Jai-Sing
Принадлежит: AnnCare Bio-Tech Center Inc.

The present invention provides a series of derivatives of stilbenoid which are useful as new inhibitory agents against head and neck squamous cell carcinoma (HNSCC) and hepatoma. 4. A pharmaceutical composition comprising the compound of .5. The pharmaceutical composition of further comprises a pharmaceutically acceptable carrier claim 4 , excipient claim 4 , diluent claim 4 , adjuvant claim 4 , medium claim 4 , or combinations thereof.6. A method of treating squamous carcinoma/hepatoma in a subject in need thereof claim 1 , the method comprising administrating to the subject an therapeutically effective amount of the compound of . This application claims priority to U.S. Priority Patent Application No. 61/807,837 filed on 3 Apr. 2013. All disclosure of which is incorporated herein by reference in its entirety.1. Field of the InventionThe present invention is related to stilbenoid compounds as inhibitors for squamous carcinoma and hepatoma and the uses thereof. More specifically, the present invention is related to compounds capable of inhibiting the cell viability and proliferation of squamous cell carcinoma and hepatocellular carcinoma, the pharmaceutical compositions of said compounds, the method for treating cancer using said compounds, and the method of manufacture of said compounds.2. The Prior ArtsHead and neck cancer is the sixth most common cancer worldwide and accounts for 6% of all cancer cases. However, it ranks the fourth most commonly occurred cancer in Taiwan. Head and neck cancer is a broad term of epithelial malignancies that occurred in the paranasal sinuses, nasal cavity, oral cavity, pharynx and larynx. Approximately 95% of histological type is squamous cell carcinoma (HNSCC), while others are salivary gland tumors, lymphomas and sarcomas. Nowadays, several risk factors related to HNSCC onset were identified. The most important risk factors in HNSCC are from tobacco and alcohol consumption. Other risk factors include inhalant industrial exposures ...

Подробнее
Номер записи: 73
12-08-2021 дата публикации

Method for synthesis of lobaric acid and analog thereof

Номер: US20210246112A1
Автор: Hong Kum Lee, II-Chan KIM, Joung Han Yim, Jun Hyuck Lee, Kwon Joo YEO, Se Jong Han, Tai Kyoung Kim, Ui Joung Youn
Принадлежит: Korea Institute of Ocean Science and Technology KIOST

The present invention can synthesize lobaric acid and four analogues thereof, which are five phenolic lichen metabolites isolated from an extract of the Antarctic lichen Stereocaulon alpinum and selectively inhibit PTP1B, by a simple, economic and efficient chemical synthesis method.

Подробнее
Номер записи: 74
12-08-2021 дата публикации

HYDROPHILIC METAL SURFACE TREATMENT AGENT

Номер: US20210246560A1
Автор: HYUGA Toshio, Nemoto Hisao, YAMADA Shoichi
Принадлежит:

The objective of the present invention is to provide a hydrophilic metal surface treatment agent by which a water-repellent property can be given to a metal surface with suppressing a corrosion and a discolorment of the metal, a method for treating a surface of a metal by using the hydrophilic metal surface treatment agent, a synthetic intermediate compound of a branched glycerol derivative as an active ingredient of the hydrophilic metal surface treatment agent, and a method for efficiently producing the synthetic intermediate compound. The hydrophilic metal surface treatment agent of the present invention is characterized in comprising the branched glycerol derivative represented by the following formula (I) as an active ingredient. 2. The hydrophilic metal surface treatment agent according to claim 1 , comprising water as a solvent.3. The hydrophilic metal surface treatment agent according to claim 2 , wherein a concentration of the branched glycerol derivative represented by the formula (I) is 0.005 mM or more and 5 mM or less.4. The hydrophilic metal surface treatment agent according to claim 2 , wherein a concentration of the branched glycerol derivative represented by the formula (I) is 0.001 mass % or more and 5 mass % or less.5. The hydrophilic metal surface treatment agent according to claim 1 , further comprising an alkaline agent.6. The hydrophilic metal surface treatment agent according to claim 1 , further comprising a surfactant.7. A method for treating a surface of a metal claim 1 , comprising the step of treating the surface of the metal by using the hydrophilic metal surface treatment agent according to .8. The method according to claim 7 , wherein the surface of the metal is treated by immersing the metal in the hydrophilic metal surface treatment agent in liquid form claim 7 , applying the hydrophilic metal surface treatment agent to the surface of the metal claim 7 , or spraying the hydrophilic metal surface treatment agent on the surface of the ...

Подробнее
Номер записи: 75
19-08-2021 дата публикации

SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN

Номер: US20210255545A1
Автор: ANRYU Yukako, ICHIKAWA Koji, MASUYAMA Tatsuro
Принадлежит: Sumitomo Chemical Company, Limited

Disclosed are a salt represented by formula (1), and an acid generator and a resist composition which include the same: 2. The salt according to claim 1 , wherein R claim 1 , Rand Reach independently represent a fluorine atom claim 1 , an iodine atom or a perfluoroalkyl group having 1 to 4 carbon atoms.3. An acid generator comprising the salt according to .4. A resist composition comprising the acid generator according to and a resin having an acid-labile group.7. The resist composition according to claim 4 , further comprising a salt generating an acid having an acidity lower than that of an acid generated from the acid generator.8. A method for producing a resist pattern claim 4 , which comprises:{'claim-ref': {'@idref': 'CLM-00004', 'claim 4'}, '(1) a step of applying the resist composition according to on a substrate,'}(2) a step of drying the applied composition to form a composition layer,(3) a step of exposing the composition layer,(4) a step of heating the exposed composition layer, and(5) a step of developing the heated composition layer. The present invention relates to a salt, an acid generator, a resist composition and a method for producing a resist pattern.Patent Document 1 mentions resist compositions each including, as acid generators, salts represented by the following formulas.Patent Document 2 mentions resist compositions including, as acid generators, salts represented by the following formulas.The present invention provides a salt and a resist composition comprising the salt capable of producing a resist pattern with CD uniformity (CDU) which is better than that of a resist pattern formed from the resist compositions including the salts mentioned above.The present invention includes the following inventions.[1] A salt represented by formula (I):wherein, in formula (I),Rrepresents a fluorine atom or a fluorinated alkyl group having 1 to 4 carbon atoms,R, Rand Reach independently represent a halogen atom, a fluorinated alkyl group having 1 to 4 ...

Подробнее
Номер записи: 76
27-08-2015 дата публикации

OPTICALLY ISOTROPIC LIQUID CRYSTAL COMPOSITION AND OPTICAL DEVICE

Номер: US20150240159A1
Автор: HASEBA YASUHIRO, Sago Koki, YAMAMOTO SHIN-ICHI
Принадлежит:

A liquid crystal composition is described, containing a chiral agent and achiral component T containing at least one compound 1 having an unsubstituted or methyl group-substituted dioxane ring and having at least one —COO— or —CFO— as a connecting group, and exhibiting an optically isotropic liquid crystal phase. 4. The liquid crystal composition of claim 2 , wherein Ris methyl.5. The liquid crystal composition of claim 1 , containing the compound 1 in an amount of 1 wt % to 90 wt % based on a total weight of the achiral component T.812-. (canceled)1416-. (canceled)17. The liquid crystal composition of claim 13 , containing the compound 3 in a total amount of 0.5 wt % to 70 wt % based on a total weight of the achiral component T.1819-. (canceled)2124-. (canceled)26. (canceled)30. The liquid crystal composition of claim 27 , containing the compound 1 in a total amount of 5 wt % to 30 wt % claim 27 , and the compound 7 in a total amount of 30 wt % to 70 wt % claim 27 , based on a total weight of the achiral component T.33. The liquid crystal composition of claim 1 , wherein a chiral nematic phase is exhibited at any temperature in a temperature range of from −20° C. to 70° C. claim 1 , and a helical pitch is 700 nm or less at least in a part of the temperature range.34. The liquid crystal composition of claim 1 , containing at least one selected from the group consisting of an antioxidant and an ultraviolet light absorbent.35. A mixture claim 1 , containing the liquid crystal composition claim 1 , and a polymerizable monomer.36. A polymer/liquid crystal composite material claim 35 , obtained by polymerizing the mixture of claim 35 , and used in a device to be driven in an optically isotropic liquid crystal phase.37. The polymer/liquid crystal composite material of claim 36 , wherein the mixture is polymerized in a non-liquid crystal isotropic phase or an optically isotropic liquid crystal phase.38. An optical device comprising a liquid crystal medium arranged between ...

Подробнее
Номер записи: 77
03-09-2015 дата публикации

PHOTORESIST COMPOSITION, COMPOUND AND PROCESS OF PRODUCING PHOTORESIST PATTERN

Номер: US20150248052A1
Автор: FUJITA Shingo, ICHIKAWA Koji, MASUYAMA Tatsuro
Принадлежит: Sumitomo Chemical Company, Limited

A photoresist composition comprising: 2. The photoresist composition according to wherein Ris a group represented by R—CO—O—* where * represents a binding site to I claim 1 , Rrepresents a C1-C22 hydrocarbon group in which a methylene group can be replaced by an oxygen atom or a carbonyl group and in which a hydrogen atom can be replaced by a hydroxyl group claim 1 , a halogen atom or a nitro group.3. The photoresist composition according to wherein Ris a C6-C24 aromatic hydrocarbon group in which a hydrogen atom can be replaced by a substituent.4. The photoresist composition according to which further comprises an onium carboxylic acid salt.7. A process for producing a photoresist pattern comprising the following steps (1) to (5):{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(1) a step of applying the photoresist composition according on a substrate,'}(2) a step of forming a composition film by conducting drying,(3) a step of exposing the composition film to radiation,(4) a step of baking the exposed composition film, and(5) a step of developing the baked composition film. This nonprovisional application claims priority under 35 U.S.C. §119(a) on Patent Application No. 2014-040138 filed in JAPAN on Mar. 3, 2014, the entire contents of which are hereby incorporated by reference.This disclosure relates to a photoresist composition, a compound and a process of producing photoresist pattern.A photoresist composition is used for semiconductor microfabrication employing a lithography process.US2012/028188A1 discloses a photoresist composition which comprises a resin having an acid-labile group, an acid generator, 2,6-diisopropylaniline and the compound represented as follow.The present invention relates to the followings:[1] A photoresist composition comprising: a resin having an acid-labile group, an acid generator, and a compound represented by formula (I):wherein R, Rand Reach independently represents a C1-C24 hydrocarbon group in which a hydrogen atom can be ...

Подробнее
Номер записи: 78
26-08-2021 дата публикации

CARBOXYLATE, CARBOXYLIC ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN

Номер: US20210263416A1
Автор: ANRYU Yukako, ICHIKAWA Koji, MASUYAMA Tatsuro
Принадлежит: Sumitomo Chemical Company, Limited

Disclosed are a carboxylate represented by formula (I), and a carboxylic acid generator and a resist composition, including the same: 2. The carboxylate according to claim 1 , wherein R claim 1 , Rand Reach independently represent a fluorine atom claim 1 , an iodine atom or a perfluoroalkyl group having 1 to 4 carbon atoms.4. The carboxylate according to claim 3 , wherein Xis an alicyclic hydrocarbon group having 3 to 36 carbon atoms which may have a fluorine atom or a hydroxy group (—CH— included in the alicyclic hydrocarbon group may be replaced by —O— claim 3 , —S— claim 3 , —CO— or —SO—) claim 3 , a group obtained by combining an alicyclic hydrocarbon group having 3 to 36 carbon atoms with a chain hydrocarbon group having 1 to 18 carbon atoms (—CH— included in the alicyclic hydrocarbon group may be replaced by —O— claim 3 , —S— claim 3 , —CO— or —SO— claim 3 , —CH— included in the chain hydrocarbon group may be replaced by —O— or —CO— claim 3 , and the alicyclic hydrocarbon group and the chain hydrocarbon group may have a fluorine atom or a hydroxy group) claim 3 , an aromatic hydrocarbon group having 6 to 36 carbon atoms which may have a fluorine atom or a hydroxy group claim 3 , a group represented by formula (aa) or a group represented by formula (bb).5. A carboxylic acid generator comprising the carboxylate according to .6. A resist composition comprising the carboxylic acid generator according to claim 5 , an acid generator other than the carboxylic acid generator claim 5 , and a resin having an acid-labile group.9. A method for producing a resist pattern claim 5 , which comprises:{'claim-ref': {'@idref': 'CLM-00006', 'claim 6'}, '(1) a step of applying the resist composition according to on a substrate,'}(2) a step of drying the applied composition to form a composition layer,(3) a step of exposing the composition layer,(4) a step of heating the exposed composition layer, and(5) a step of developing the heated composition layer. The present invention ...

Подробнее
Номер записи: 79
06-11-2014 дата публикации

PRODUCTION OF CYCLIC ACETALS OR KETALS USING SOLID ACID CATALYSTS

Номер: US20140330029A1
Автор: Billodeaux Damon Ray, Howard Adam Scott, Little James Lon, McMurray Brian David, Terrill Daniel Latham
Принадлежит: EASTMAN CHEMICAL COMPANY

A process for making a cyclic compounds such as cyclic acetal or cyclic ketones by feeding aldehyde or ketone compounds and polyhydroxyl compounds to a reaction zone at a molar ratio of polyhydroxyl compounds to aldehyde or ketone compounds of at least 3:1, reacting these compounds in the presence of a solid acid such as an acidic ion exchange resin, to generate a liquid reaction mixture without separating water from the reaction mixture as it is being formed in the reaction mixture, withdrawing the liquid reaction mixture from the reaction zone as a liquid product stream, and feeding the liquid reaction product stream to a distillation column to separate cyclic acetal compounds from unreacted polyhydroxyl compounds, and optionally recycling back the unreacted polyhydroxyl compounds to the reaction zone. The process produces cyclic acetal compounds in yields of at least 90% with long catalyst life. The process is also suitable to make cyclic ketals from ketone compounds. 2. The liquid composition of claim 1 , comprising the following mole percentages:a) water: at least 3 mole % and up to 25 mole %;b) polyhydroxyl compounds: at least 50 mole % and up to 95 mole %;c) cyclic compounds: at least 3 mole % and up to 25 mole %.3. The liquid composition of claim 2 , comprising the following mole percentages:a) water: at least 9 mole % and up to 25 mole %;c) cyclic compounds: at least 9 mole % and up to 25 mole %.4. The liquid composition of claim 1 , comprising the following mole percentages:a) water: at least 12 mole % and up to 18 mole %;b) polyhydroxyl compounds: at least 70 mole % and up to 95 mole %;c) cyclic compounds: at least 12 mole % and up to 25 mole %.5. The liquid composition of claim 1 , wherein the cyclic compounds comprise cyclic acetals.6. The liquid composition of claim 1 , wherein the amount of any other liquid ingredient in the liquid composition does not exceed 8 mole %.7. The liquid composition of claim 6 , wherein the amount of any other liquid ...

Подробнее
Номер записи: 80
30-08-2018 дата публикации

MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20180242582A1
Автор: Boebel Timothy A., Bravo-Altamirano Karla, Daeuble, Lu Yu, Meyer Kevin G., Nugent Benjamin M., SR. John F., Yao Chenglin
Принадлежит:

This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. The compound according to claim 1 , wherein X and Y are hydrogen.3. The compound according to claim 1 , wherein X is C(O)Rand Y is hydrogen.48.-. (canceled)9. A composition for the control of a fungal pathogen including at least one of the compounds of and at least one additional compound selected from the group consisting of: a phytologically acceptable carrier material claim 1 , a second fungicide claim 1 , an insecticide claim 1 , a nematocides claim 1 , a miticide claim 1 , an arthropodicide claim 1 , a bactericide.10. The composition for the control of a fungal pathogen according to claim 9 , wherein the at least one additional compound is at least one phytologically acceptable carrier material.11Mycosphaerella graminicolaSeptoria triticiPuccinia triticinaPuccinia striiformisVenturia inaequalisUstilago maydisUncinula necatorRhynchosporium secalisMagnaporthe griseaPhakopsora pachyrhiziLeptosphaeria nodorumBlumeria graministriticiBlumeria graminishordeiErysiphe cichoracearumGlomerella lagenariumCercospora beticolaAlternaria solaniPyrenophora teres. The compositions according to claim 9 , wherein the fungal pathogen is at least one pathogen selected from the group consisting of: Leaf Blotch of Wheat (; anamorph: ) claim 9 , Wheat Brown Rust () claim 9 , Stripe Rust () claim 9 , Scab of Apple () claim 9 , Blister Smut of Maize () claim 9 , Powdery Mildew of Grapevine () claim 9 , Barley Scald () claim 9 , Blast of Rice () claim 9 , Rust of Soybean () claim 9 , Glume Blotch of Wheat () claim 9 , Powdery Mildew of Wheat (f sp. ) claim 9 , Powdery Mildew of Barley (f. sp. ) claim 9 , Powdery Mildew of Cucurbits () claim 9 , Anthracnose of Cucurbits () claim 9 , Leaf Spot of Beet () claim 9 , Early Blight of Tomato () claim 9 , and Net Blotch of Barley ().12Septoria triticiPuccinia triticinaPhakopsora pachyrhizi. The composition according to wherein the fungal pathogen is ...

Подробнее
Номер записи: 81
20-11-2014 дата публикации

METHODS OF PREPARING ICOTINIB AND ICOTINIB HYDROCHLORIDE, AND INTERMEDIATES THEREOF

Номер: US20140343283A1
Автор: Hu Shaojing, Li Zongquan, Long Wei, WANG FEI
Принадлежит: BETTA PHARMACEUTICALS CO., LTD.

The present invention relates to the technical field of medicine, and specifically provides methods for preparing Icotinib, Icotinib hydrochloride, and intermediates thereof. These methods avoid the use of phosphorus oxychloride, thereby greatly reducing the emission of pollutants, which is of major benefits to the economy and environment. 2. The compound of claim 1 , wherein each of Rand Rindependently is methyl or ethyl.3. The compound of claim 1 , wherein Rand Rare both methyl.4. The compound of claim 1 , wherein Rand Rare both ethyl.5. The compound of claim 1 , wherein Rand R claim 1 , together with the N atom to which they are attached claim 1 , form a 3 claim 1 , 4 claim 1 , or 5-membered ring.6. The compound of claim 1 , wherein Rand R claim 1 , together with the N atom to which they are attached claim 1 , form a 5 claim 1 , 6 claim 1 , or 7-membered ring.9. The method of claim 8 , wherein each of Rand Rindependently is methyl claim 8 , ethyl claim 8 , isopropyl claim 8 , tert-butyl claim 8 , or benzyl.10. The method of claim 8 , wherein Rand Rare both methyl.11. The method of claim 8 , wherein Rand Rare both ethyl.18. The method of claim 17 , wherein compound A is converted to compound B by reacting compound A with a proton-donating agent claim 17 , metal hydride claim 17 , hydrazine claim 17 , or alkali ammonia solution via catalytic hydrogenation reaction or metal-involved reduction reaction; the metal is Mg claim 17 , Al claim 17 , Zn claim 17 , Fe claim 17 , Sn claim 17 , Pb or Cu; the proton-donating agent is acetic acid claim 17 , formic acid and/or trifluoroacetic acid (TFA); the catalyst applied in the catalytic hydrogenation reaction is Pd/Carbon or Raney Ni; the metal hydride is sodium hydride or potassium hydride; and the alkali metal is sodium or potassium.19. The method of claim 18 , wherein compound A claim 18 , ferrous powder claim 18 , and acetic acid in methanol solution are fully mixed claim 18 , and heated to reflux until the reaction is ...

Подробнее
Номер записи: 82
15-08-2019 дата публикации

PHOTOINITIATORS WITH PROTECTED CARBONYL GROUP

Номер: US20190248757A1
Автор: Abuelyaman Ahmed S., Chou Shih-Hung, Gong Tao, Homnick Paul J., Mahoney Wayne S., Oxman Joel D., Volp Kelly A.
Принадлежит:

Disclosed are of the protected photoinitiators of the formula: wherein Aryl1 is an aromatic or heteroaromatic ring; Aryl2 is an aromatic ring; each Ris an alkyl, an aryl, an electron donating group or an electron withdrawing group, and subscript a is 0 to 3; each Ris an alkyl, an aryl, an electron donating group or an electron withdrawing group, and subscript b is 0 to 3; Prot is a protected carbonyl group. 3. The protected photoinitiator_of wherein Arylis selected from phenyl and napthyl.4. The protected photoinitiator of wherein Prot is a cyclic or acyclic ketal.5. The protected photoinitiator of wherein Prot is selected from thioketals claim 1 , dithioketals claim 1 , O-substituted cyanohydrins claim 1 , substituted hydrazones claim 1 , oxazolidines claim 1 , imidazolidines and thiazolidines protecting groups.6. The protected photoinitiator of having at least one electron-donating Ror Rgroups.7. The protected photoinitiator of having at least one electron-withdrawing Ror Rgroups.8. A polymerizable composition comprising at least one free-radically polymerizable monomer claim 1 , and the protected photoinitiator of .9. The polymerizable composition of wherein the monomer is a (meth)acrylate monomer.10. The polymerizable composition of wherein the monomer is a multifunctional (meth)acrylate monomer.11. The polymerizable composition of comprisingi. up to 100 parts by weight, preferably 85 to 99.5 parts by weight of an (meth)acrylic acid ester;ii. 0 to 15 parts by weight, preferably 0.5 to 15 parts by weight of an acid functional ethylenically unsaturated monomer;iii. 0 to 15 parts by weight of a non-acid functional, ethylenically unsaturated polar monomer;iv. 0 to 5 parts by weight vinyl monomer;v. 0 to 100 parts by weight of a multifunctional (meth)acrylate, preferably 50 to 100 parts by weight, relative to i-iv, wherein the sum of I. to Vii is 100%.12. The polymerizable composition of comprising a reactive oligomer having pendent polymerizable groups comprising:a) ...

Подробнее
Номер записи: 83
27-11-2014 дата публикации

Acetals Esters Produced from Purified Glycerin for Use and Application as Emollients, Lubricants, Plasticizers, Solvents, Coalescents, Humectant, Polymerization Monomers, Additives to Biofuels

Номер: US20140350269A1
Автор: EIJI BORGES SATO Marcelo
Принадлежит: GLYCEROSOLUTION QUÍMICA LTDA.

It refers to a new group of acetal monoesters and diesters which have in its structure the ester function and cyclic ethers that give these products excellent properties as solvency, plasticity in polymers, solubility in polar and nonpolar means, spreadability, wetting, low volatility, non-toxicity and biodegradability. These properties make these products excellent candidates as solvents in formulations of pesticides, agricultural herbicides, for the paint and leather industry in domestic or industrial hygiene formulations; as plasticizers for polymers such as polyvinyl chloride, nitrocellulose, cellulose, acrylics, polyvinyl vinyl and its copolymers; as lubricants in industrial formulations, textile industry; as emollients agents which donate oiliness for the cosmetic industry; as wetting agents that are commonly used, and as biodiesel additives to reduce the freezing point and to improve its combustion. 1. ACETAL ESTERS PRODUCED FROM PURIFIED GLYCERIN FOR USAGE AND APPLICATIONS AS EMOLLIENTS , LUBRICANTS , PLASTICIZERS , SOLVENTS , COALESCENTS , HUMECTANTS , POLYMERIZATION MONOMERS , ADDITIVES TO BIOFUELS , more particularly it concerns mono- and diesters of acetals characterized by:being produced from glycerine, organic aldehydes, and carboxylic or dicarboxylic acids such as humectants, solvents, additives, lubricants, softeners, plasticizers, surfactants, dispersants;products produced from the techniques described may contain natural antioxidants from purified glycerin whose process prevents distillation and preserves the presence of tocopherols and other active ingredients such as sterols and squalene;the glycerin used may be technical distilled glycerin, USP glycerin, blond glycerin, and preferably purified glycerin;organic aldehydes can be propinaldehyde, isoamialdehyde, nonaldehyde, decanaldehyde, isotridecilaldehyde, furfuraldehyde, benzaldehyde, and preferably butyraldehyde, isobutyraldehyde and ethylhexaldehyde;Carboxylic acids are acetic acid, propionic ...

Подробнее
Номер записи: 84
22-09-2016 дата публикации

PROCESS FOR PREPARING CHLOROACETALDEHYDE ACETALS

Номер: US20160272610A1
Автор: DOERING Wolfgang, FLEISCHMANN Gerald, KRUEGER Benno, PETERSEN Hermann
Принадлежит:

The invention relates to a process for preparing chloroacetaldehyde acetals of monohydric, dihydric or higher-functionality aliphatic alcohols, in which the chloroacetaldehyde acetal is obtained from an aqueous chloroacetaldehyde solution in the presence of the alcohol to be acetalized and an acid catalyst by azeotropic removal of water with the aid of a solvent, wherein the solvent is a halogenated solvent. 1. A process for preparing a chloroacetaldehyde acetal of an aliphatic alcohol , wherein the chloroacetaldehyde acetal is obtained from an aqueous chloroacetaldehyde solution in a presence of the aliphatic alcohol to be acetalized and an acid catalyst by azeotropic removal of water with the aid of a solvent , wherein the solvent is a halogenated solvent.2. The process as claimed in claim 1 , wherein the halogenated solvent is a singly or multiply chlorinated or fluorinated hydrocarbon which has from one to five carbon atoms and forms an azeotrope having a boiling point in a range from 25° C. to 80° C. with water under atmospheric pressure.3. The process as claimed in claim 1 , wherein the halogenated solvent is trichloromethane.4. The process as claimed in claim 1 , wherein the aliphatic alcohol to be acetalized is a monohydric claim 1 , dihydric or higher-functionality aliphatic alcohol having from one to twelve carbon atoms.5. The process as claimed in claim 1 , wherein the acid catalyst is a member selected from the group consisting of an inorganic acid claim 1 , an organic acid and a strong acid ion exchange resin containing sulfonic acid groups.6. The process as claimed in claim 1 , wherein the acid catalyst is present in an amount of from 0.01 mol % to 2 mol % based on the chloroacetaldehyde used.7. The process as claimed in claim 2 , wherein the halogenated solvent is trichloromethane.8. The process as claimed in claim 7 , wherein the aliphatic alcohol to be acetalized is a monohydric claim 7 , dihydric or higher-functionality aliphatic alcohol having ...

Подробнее
Номер записи: 85
04-12-2014 дата публикации

PRODUCTION OF CYCLIC ACETALS BY REACTIVE DISTILLATION

Номер: US20140357875A1
Автор: Billodeaux Damon Ray, Huss Robert Scott, JR. Jerome Leonard, Stavinoha, Terrill Daniel Latham
Принадлежит: EASTMAN CHEMICAL COMPANY

Cyclic acetals can be produced in a reactive distillation apparatus by combining a polyhydroxyl compound and an aldehyde. High concentrations of cyclic acetals are removed as liquid products from the column while water is removed as an overhead vapor stream. 1. A liquid composition comprising water in an amount from 0 to 8 mole % , aldehyde compounds in an amount from 0 to 5 mole % , cyclic acetal compounds in an amount from 10 mole % to 90 mole % , polyhydroxyl compounds present in an amount from 10 mole % to 90 mole % , and a catalyst in an amount of from 0-1 mole % , wherein the stated mole percentages are based on the mole of all ingredients within the liquid composition.2. The process of claim 1 , wherein the liquid composition comprises water in an amount from 0 to 3 mole % claim 1 , aldehyde compounds in an amount from 0 to 2 mole % claim 1 , cyclic acetal compounds in an amount from 25 mole % to 75 mole % claim 1 , polyhydroxyl compounds in an amount from 25 mole % to 75 mole %.3. The process of claim 2 , wherein the liquid composition comprises water in an amount from 0 to 0.5 mole % claim 2 , aldehyde compounds in an amount from 0 to 0.25 mole % claim 2 , cyclic acetal compounds in an amount from 50 mole % to 60 mole % claim 2 , and polyhydroxyl compounds in an amount from 40 mole % to 50 mole %. This application is a Continuation of U.S. application Ser. No. 13/168,229 filed Jun. 24, 2011, the contents of which are incorporated by reference in their entirety herein.The invention relates to the production of cyclic acetals in high yield by reactive distillation and compositions containing high yields of cyclic acetals.Ether alcohols, such as 2-butoxyethanol, have important industrial functions in such products such as cleaning supplies and coating materials. In the past, the manufacture of these products has been based on a process relying on a reaction between an alcohol and ethylene oxide. This conventional process has proven to be somewhat inefficient, ...

Подробнее
Номер записи: 86
13-08-2020 дата публикации

COMPOUND, LIQUID CRYSTAL COMPOSITION AND PHOTOELECTRIC DISPLAY DEVICE THEREOF

Номер: US20200255738A1
Автор: CHEN Zhaoyuan, Han Wenming, MA Wenyang, Zhang Wenqi
Принадлежит: Jiangsu Hecheng Display Technology Co., Ltd.

A compound having the structure of general formula I is useful as a liquid crystal composition and as a photoelectric display device including the liquid crystal composition. The compound having the structure of general formula I is chemically and physically stable, and has higher clearing point, and both large dielectric anisotropy and large optical anisotropy at the same time. The compound having the structure of general formula I is well compatible with other liquid crystal compounds when applied in a liquid crystal composition, the composition has good stability especially in a low-temperature environment, the characteristic of fast response and a wide range of applicabilities, especially applicable to the IPS-type and TN-TFT-type liquid crystal display devices. 2. The compound according to claim 1 , wherein X represents —F or —OCF.3. The compound according to claim 2 , wherein Zrepresents a single bond or —CFO—.4. The compound according to claim 3 , wherein Zand Zeach independently represents a single bond claim 3 , —CHCH— claim 3 , —CHO— or —CFO—.5. The compound according to claim 4 , wherein at least one of Z claim 4 , Zand Zis not a single bond.7. The compound according to claim 1 , wherein at most four of Lto Lrepresents —F.8. The compound according to claim 7 , wherein Land Lboth represent —H.10. The compound according to claim 9 , wherein when Lrepresents —F claim 9 , X represents —F.12. The liquid crystal composition according to claim 9 , wherein the compound of general formula I is selected from the group consisting of the compounds of general formulas I-1 to I-12 according to .13. The liquid crystal composition according to claim 12 , wherein the compound of general formula I provides 1-50% of the total weight of the liquid crystal composition claim 12 , the compound selected from the group consisting of the compounds of general formulas II-1 to II-4 provides 5-75% of the total weight of the liquid crystal composition claim 12 , and the compound ...

Подробнее
Номер записи: 87
28-09-2017 дата публикации

MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20170273303A1
Автор: Bravo-Altamirano Karla, Daeuble John F., DeKorver Kyle A., DeLorbe Johnathan E., Heemstra Ronald J., Meyer Kevin G., Yao Chenglin
Принадлежит:

This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. The compound according to claim 1 , wherein X and Y are hydrogen.3. The compound according to claim 2 , wherein Ris alkyl or aryl claim 2 , each optionally substituted with 0 claim 2 , 1 or multiple R.4. The compound according to claim 2 , wherein Ris hydrogen or alkyl claim 2 , each optionally substituted with 0 claim 2 , 1 or multiple R.5. The compound according to claim 1 , wherein X is C(O)Rand Y is hydrogen.6. The compound according to claim 5 , wherein Ris alkyl or aryl claim 5 , each optionally substituted with 0 claim 5 , 1 or multiple R.7. The compound according to claim 5 , wherein Ris hydrogen or alkyl claim 5 , each optionally substituted with 0 claim 5 , 1 or multiple R.8. The compound according to claim 1 , wherein X is hydrogen and Y is Q.9. The compound according to claim 8 , wherein Ris alkyl or aryl claim 8 , each optionally substituted with 0 claim 8 , 1 or multiple R.10. The compound according to claim 8 , wherein Ris hydrogen or alkyl claim 8 , each optionally substituted with 0 claim 8 , 1 or multiple R.11. The compound according to claim 9 , wherein Ris hydrogen.12. The compound according to claim 9 , wherein Ris —C(O)R or —CHOC(O)R.13. The compound according to claim 12 , wherein Ris alkyl or alkoxy claim 12 , each optionally substituted with 0 claim 12 , 1 claim 12 , or multiple R.14. The compound according to claim 13 , wherein Ris —CH claim 13 , —CH(CH) claim 13 , —CHOCHCH claim 13 , or —CHCHOCH.15. A composition for the control of a fungal pathogen including at least one of the compounds of Formula I and at least one additional compound selected from the group consisting of: a phytologically acceptable carrier material claim 13 , a second fungicide claim 13 , an insecticide claim 13 , a nematocide claim 13 , a miticide claim 13 , an arthropodicide claim 13 , and a bactericide.16. The composition according to claim 15 , wherein the least one ...

Подробнее
Номер записи: 88
11-11-2021 дата публикации

BENZAMIDE DERIVATIVES AS CGAS-STING PATHWAY AGONISTS

Номер: US20210347752A1
Автор: Chang Jinhong, Du Yanming, Guo Ju-Tao
Принадлежит:

Pharmaceutical compositions of the invention comprise functionalized benzamide derivatives useful as cyclic GMP-AMP synthase-Stimulator of interferon gene (cGAS-STING) pathway agonists, and useful for treating viral diseases and boost antitumor immunity. 14. A composition comprising an effective amount of at least one compound according to .15. The composition according to claim 14 , further comprising at least one excipient.16. A compound selected from the group consisting of:3,4-dimethoxy-N-(naphthalen-1-yl)benzamideN-(naphthalen-1-yl)benzo[d][1,3]dioxole-5-carboxamideN-(naphthalen-1-yl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide3-methoxy-N-(naphthalen-1-yl)benzamide2-bromo-6-methoxy-N-(naphthalen-1-yl)benzamide2-bromo-N-(naphthalen-1-yl)benzamide6-bromo-N-(naphthalen-1-yl)benzo[d][1,3]dioxole-5-carboxamideN-(naphthalen-1-yl)-3,4-dihydro-2H-benzo[b][1,4]dioxepine-7-Carboxamide3,4-dimethoxy-N-(naphthalen-1-yl)benzamideN-(naphthalen-1-yl)benzamide2-chloro-N-(naphthalen-1-yl)benzamide4-fluoro-N-(naphthalen-1-yl)-2-(trifluoromethyl)benzamide2,4-difluoro-N-(naphthalen-1-yl)benzamide2-fluoro-N-(naphthalen-1-yl)-5-nitrobenzamide2-chloro-N-(naphthalen-1-yl)nicotinamide4-bromo-2-chloro-N-(naphthalen-1-yl)benzamide2-bromo-4,5-dimethoxy-N-(naphthalen-1-yl)benzamide2-bromo-4,5-difluoro-N-(naphthalen-1-yl)benzamide2-bromo-4-methoxy-N-(naphthalen-1-yl)benzamide6-bromo-N-(5,6,7,8-tetrahydronaphthalen-1-yl)benzo[d][1,3]dioxole-5-carboxamide6-bromo-N-methyl-N-(naphthalen-1-yl)benzo[d][1,3]dioxole-5-carboxamide6-bromo-N-(2,3-dimethylphenyl)benzo[d][1,3]dioxole-5-carboxamide6-bromo-N-(3-cyano-2-fluorophenyl)benzo[d][1,3]dioxole-5-carboxamide6-bromo-N-(2,3-dihydro-1H-inden-4-yl)benzo[d][1,3]dioxole-5-carboxamide6-bromo-N-(3-fluoro-2-methylphenyl)benzo[d][1,3]dioxole-5-carboxamide6-bromo-N-(2-bromo-3-methylphenyl)benzo[d][1,3]dioxole-5-carboxamide6-bromo-N-(2,3-dichlorophenyl)benzo[d][1,3]dioxole-5-carboxamide6-bromo-N-(2-fluorophenyl)benzo[d][1,3]dioxole-5-carboxamide6-bromo-N-(3- ...

Подробнее
Номер записи: 89
11-12-2014 дата публикации

METHOD AND DEVICE FOR THE SYNTHESIS OF ARTEMISININ

Номер: US20140364630A1
Автор: Kopetzki Daniel, Lévesque Francois, Seeberger Peter H.
Принадлежит: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSC

The present invention is directed to a method for producing artemisinin having the formula 2. The method according to claim 1 , wherein all three steps i) claim 1 , ii) and iii) are performed in a continuous manner.3. The method according to claim 1 , wherein the photooxidation of step i) is carried out under pressure ranging from 1.5 bar to 15 bar.4. The method according to claim 1 , wherein all three steps i)-iii) are carried out under pressure.6. The method according to claim 1 , wherein the continuous flow reactor comprises a tube made of a fluorinated or perfluorinated alkylene polymer wherein the photooxidation of dihydroartemisinic acid takes place.7. The method according to claim 1 , wherein trifluoroacetic acid is used for the acid mediated cleavage.8. (canceled)9. A photochemical reactor for the production of artemisinin from dihydroartemisinic acid comprisinga light source,mixing device for mixing oxygen with a solution of dihydroartemisinic acid,reactor compartment exposed to the light source for irradiating the mixture of the solution of dihydroartemisinic acid and oxygen when the mixture passes the reactor compartment, anda back pressure regulator.10. The photochemical reactor according to claim 9 , wherein the reactor compartment is a tubing.11. The photochemical reactor according to claim 9 , wherein the mixing device is a T-mixer valve.12. The photochemical reactor according to further comprisinga box which is impervious to light with light reflecting inner walls and one opening through which the tubing enters the box and another opening through which the tubing leaves the box andmultiple loops of the tubing arranged in the inside of the box, wherein the tubing has an inlet for a mixture of dihydroartemisinic acid and oxygen on its one end before entering the box and an outlet for the reacted products on the opposite end after leaving the box.13. The photochemical reactor according to further comprisinga cooling liquid and a chiller.14. A continuous ...

Подробнее
Номер записи: 90
29-09-2016 дата публикации

ALKENYL DIOXANE COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE

Номер: US20160280996A1
Автор: HIRATA Kenji, OKUMURA Kazuo
Принадлежит:

A problem is to provide a liquid crystal compound satisfying at least one physical property such as high stability to heat and light, high clearing point, low minimum temperature of liquid crystal phase, small viscosity, suitable optical anisotropy, large dielectric anisotropy, suitable elastic constant and excellent compatibility with other liquid crystal compounds, a liquid crystal composition containing the compound, and a liquid crystal display device including the composition. 3. The compound according to , wherein , in formula (1-1) , formula (1-2) or formula (1-3) described in , Ris alkenyl having 2 to 5 carbons; ring Aand ring Aare each independently 1 ,4-cyclohexylene , 1 ,4-phenylene , or 1 ,4-phenylene in which arbitrary hydrogen is replaced by fluorine; Z , Zand Zare each independently a single bond , —COO— or —CFO—; Xis hydrogen , fluorine , —CFor —OCF; and L , L , Land Lare each independently hydrogen or fluorine.5. The compound according to , wherein , in formula (1-a) to formula (1-s) described in , Ris vinyl , 1-propenyl , 3-butenyl or 3-pentenyl.6. The compound according to , wherein , in formula (1-a) to formula (1-s) described in , Ris vinyl , 1-propenyl , 3-butenyl or 3-pentenyl; Xis fluorine; and Land Lare hydrogen or fluorine.7. The compound according to , wherein , in formula (1-a) to formula (1-s) described in , Ris vinyl , 1-propenyl , 3-butenyl , or 3-pentenyl; Xis —OCF; and Land Lare each independently hydrogen or fluorine.8. A liquid crystal composition claim 1 , containing at least one compound according to .13. A liquid crystal display device claim 8 , including the liquid crystal composition according to . The invention relates to a liquid crystal compound, a liquid crystal composition and a liquid crystal display device. More specifically, the invention relates to an alkenyl-dioxane compound, a liquid crystal composition that contains the compound and has a nematic phase, and a liquid crystal display device including the composition. ...

Подробнее
Номер записи: 91
29-08-2019 дата публикации

SPONTANEOUS ALIGNMENT ASSISTANT FOR LIQUID CRYSTAL COMPOSITIONS

Номер: US20190264108A1
Автор: Akiyama Hidenari, Hayashi Masanao, Inoue Yuuichi, Kimura Masaomi, Kusumoto Tetsuo
Принадлежит: DIC CORPORATION

The spontaneous orientation aid for a liquid crystal composition provides storage stability and allows liquid crystal molecules to be vertically aligned without a PI layer when added to a liquid crystal composition. The spontaneous orientation aid for a liquid crystal composition includes a compound having a partial structure represented by formula (i), particularly in which Kis represented by one of formula (K-1) to formula (K-11). When used in a liquid crystal composition, the spontaneous orientation aid can adsorb to substrates sandwiching a liquid crystal composition (liquid crystal layer) and keep the liquid crystal molecules aligned in a vertical direction. The spontaneous orientation aid makes it possible to align liquid crystal molecules without a PI layer (to induce vertical alignment of liquid crystal molecules under no applied voltage and to achieve horizontal alignment of the liquid crystal molecules under an applied voltage). 117-. (canceled)20. The spontaneous orientation aid for a liquid crystal composition according to claim 19 ,{'sup': i1', 'i1', 'i1', 'i1', 'i1, "wherein monovalent organic groups having substituents represented by Pand K, respectively, are located on the same A's or on different A's with no Zother than a single bond interposed therebetween."}22. A liquid crystal composition comprising the spontaneous orientation aid for a liquid crystal composition according to and having a negative dielectric anisotropy (Δε).25. The liquid crystal composition according to claim 22 , further comprising:at least one polymerizable compound.27. A liquid crystal display element comprising:two substrates; and{'claim-ref': {'@idref': 'CLM-00022', 'claim 22'}, 'a liquid crystal layer including the liquid crystal composition according to provided between the two substrates.'}29. The liquid crystal display element according to claim 27 , which is for active matrix driving.30. The liquid crystal display element according to claim 27 , which is a PSA type ...

Подробнее
Номер записи: 92
27-10-2016 дата публикации

Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain

Номер: US20160311792A1
Автор: Choi Yong Moon
Принадлежит:

The present invention relates to sulfamate derivative compounds and a composition for treating and/or alleviating pain containing the sulfamate derivative compounds or a pharmaceutically acceptable salt thereof as an active ingredient. More specifically the present invention relates to a pharmaceutical composition for treating or alleviating pain containing a sulfamate derivative compound and/or a pharmaceutically acceptable salt thereof as an active ingredient. Furthermore, the present invention relates to a method for treatment or alleviation of pain comprising administering a sulfamate derivative compound in a pharmaceutically effective amount to a subject in need of treatment or alleviation of pain. 2. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein X is H claim 1 , OMe claim 1 , F claim 1 , or I; and n is an integer from 1-4.3. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein l or m are each independently an integer 0 or 1.4. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein Rand Rare each independently methyl claim 1 , ethyl claim 1 , isopropyl or Rand Rtogether with the carbon atom to which they attach form a cyclopentyl or a cyclohexyl group.5. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein Rand Rare each independently hydrogen or methyl.6. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , whereinX is chlorine, fluorine, iodine, bromine, methoxy or H;n is an integer from 1-4;{'sup': 1', '2, 'sub': 1', '2, 'Rand Rare each dependently selected from the group consisting of methyl, ethyl and isopropyl, or Rand Rtogether with the carbon atom to which they attach form a cyclopentyl or a cyclohexyl ring;'}{'sup': 3', '4, 'Rand Rare each dependently selected from the group consisting of H, methyl, ethyl, and isopropyl;'}l and m are each dependently an integer ...

Подробнее
Номер записи: 93
05-11-2015 дата публикации

POLYTHIOLS AS CIS/TRANS ISOMERIZATION CATALYSTS FOR UNSATURATED COMPOUNDS

Номер: US20150315113A1
Автор: GREINER Nadine, STEMMLER René Tobias
Принадлежит:

The present invention relates to a process of a cis/trans isomerization of an unsaturated compound A being selected from the group consisting of unsaturated ketones, unsaturated ketals, unsaturated aldehydes, unsaturated acetals, unsaturated carboxylic acids, esters of an unsaturated carboxylic acid and amides of an unsaturated carboxylic acid using polythiol as cis/trans isomerization catalyst. It has been observed that the isomerization is very efficient and fast. 1. A process of a cis/trans isomerization of an unsaturated compound A being selected from the group consisting of unsaturated ketones , unsaturated ketals , unsaturated aldehydes , unsaturated acetals , unsaturated carboxylic acids , esters of an unsaturated carboxylic acid and amides of an unsaturated carboxylic acid comprising the stepsa) providing a cis or a trans isomer of a unsaturated compound A;b) adding a polythiol to the cis or trans isomer of the unsaturated compound A of step a);c) heating the mixture of polythiol and cis or trans isomer of the unsaturated compound A to a temperature of between 20° C. and the boiling point of the unsaturated compound A, particularly between 50° C. and the boiling point of the unsaturated compound A;leading to a mixture of cis/trans isomers of the unsaturated compound A.2. The process according to wherein the unsaturated compound A is an unsaturated ketone or unsaturated ketal or an unsaturated aldehyde or an unsaturated acetal.3. The process according to wherein the amount of polythiol is between 1 and 20% by weight in relation to the amount of the unsaturated compound A.5. The process according to wherein the polythiol is 4 claim 1 ,4′-dimercaptobiphenyl or 4 claim 1 ,4′-thiodibenzenethiol.6. The process according to wherein it is undertaken in the presence of a polar solvent claim 1 , particularly a polar solvent which is selected from the group consisting of ionic liquids claim 1 , particularly 1-butyl-3-methylimidazolium bromide claim 1 , N claim 1 ,N- ...

Подробнее
Номер записи: 94
03-11-2016 дата публикации

BROMINE-SENSITIZED SOLAR PHOTOLYSIS OF CARBON DIOXIDE

Номер: US20160319423A1
Автор: BRAIMAN Mark S.
Принадлежит:

There is described a process for depositing carbon on a surface, comprising, while contacting a mixture of COand Brwith a polar substrate presenting apposed surfaces, exposing a sufficient area of said mixture in the region of said apposed surfaces to light of sufficient intensity and frequency to result in deposition of carbon on at least some of said apposed surfaces. Other embodiments are also described. 119-. (canceled)20. A composition of matter comprising a polar substrate presenting apposed surfaces and a mixture of COand Brin contact with at least some of said apposed surfaces.21. A composition of matter according to claim 20 , wherein said polar substrate is a non-carbonaceous polar substrate.22. A composition of matter according to claim 21 , wherein said polar substrate is selected from the group consisting of silica claim 21 , silica-based glasses claim 21 , alumina and titania claim 21 , and mixtures thereof.23. A composition of matter according to claim 22 , wherein said polar substrate is in particulate form.24. A composition of matter according to claim 22 , wherein said polar substrate is selected from sand claim 22 , silica gel claim 22 , powdered alumina claim 22 , titania claim 22 , quartz sand claim 22 , glass spheres claim 22 , and glass wool.25. A composition of matter according to claim 20 , wherein the polar substrate claim 20 , COand Brand are contained in a UV and visible-light transparent region of a reaction vessel.26. A composition of matter according to claim 25 , wherein said UV and visible-light transparent region is transparent to light having a wavelength of 300 to 500 nm.27. A composition of matter according to claim 25 , wherein said UV-light transparent region is also transparent to visible light.28. A composition of matter according to any of wherein the reaction vessel is made from quartz or borosilicate glass.2937-. (canceled)38. A reactor for utilizing solar energy and bromine to reduce CO claim 25 , the reactor comprising a ...

Подробнее
Номер записи: 95
24-09-2020 дата публикации

LIQUID-CRYSTALLINE COMPOUNDS

Номер: US20200299580A1
Автор: Brocke Constanze, Laut Sven Christian, LINKE Katharina
Принадлежит: Merck Patent GmBH

Compounds of the formula I, 2. A compound according to claim 1 , wherein{'sup': '4', 'Ldenotes H.'}3. A compound according to claim 1 , wherein Rdenotes alkyl having 1 to 8 carbon atoms or alkenyl having 2 to 8 carbon atoms.4. A compound according to claim 1 , wherein Xdenotes F claim 1 , OCFor CF.5. A compound according to claim 1 , wherein Land Leach denote F.6. A compound according to claim 1 , wherein Ydenotes O.7. A compound according to claim 1 , wherein Ydenotes CH.9. A compound according to claim 1 , wherein Rdenotes a straight-chain alkyl radical having 1 to 7 C atoms or an unbranched alkenyl radical having 2 to 8 C atoms.11. A liquid-crystalline medium comprising at least two mesogenic compounds claim 1 , which comprises at least one compound of the formula I according to .12. Electro-optical liquid-crystal display comprising a liquid-crystalline11. cording to .13. A compound according to claim 8 , wherein Rdenotes alkyl having 1 to 8 carbon atoms or alkenyl having 2 to 8 carbon atoms.14. A compound according to claim 1 , wherein:{'sup': 4', '5, 'Land Leach denote H;'}{'sup': '1', 'Rdenotes alkyl having 1 to 8 carbon atoms or alkenyl having 2 to 8 carbon atoms;'}{'sup': '1', 'Xdenotes F, OCF3 or CF3; and'}{'sup': 1', '2, 'Land Leach denote F.'}15. A compound according to claim 1 , wherein Ldenotes H. An aspect of the invention relates to compounds of the formula I as defined below, which contain, as structural elements, a combination of a 1,4-substituted cyclohexene ring besides a dioxane or tetrahydropyran ring and a substituted biphenyl group. In addition, the invention encompasses a process for the preparation of these compounds, liquid-crystalline media comprising at least one compound of the formula I, and the use thereof as component(s) in liquid-crystalline media. In addition, the present invention relates to liquid-crystal and electro-optical display elements which contain the liquid-crystalline media according to the invention.In previous years, ...

Подробнее
Номер записи: 96
10-10-2019 дата публикации

LIGHT GENERATING MICROCAPSULES FOR SELF-HEALING POLYMER APPLICATIONS

Номер: US20190309105A1
Автор: Campbell Eric J., Czaplewski-Campbell Sarah K., Kuczynski Joseph, Tofil Timothy J.
Принадлежит:

A self-healing polymeric material includes a polymeric matrix material, wherein dispersed within the polymeric matrix material is a mixture of materials that includes monomers and a photoinitiator, and a plurality of light generating microcapsules dispersed in the polymeric matrix material. Each light generating microcapsule encapsulates multiple reactants that undergo a chemiluminescent reaction. The chemiluminescent reaction generates a photon having a wavelength within a particular emission range that is consistent with an absorption range of the photoinitiator. 1. A self-healing polymeric material comprising:a polymeric matrix material;wherein dispersed within the polymeric matrix material is a mixture of materials that includes monomers and a photoinitiator; anda plurality of light generating microcapsules dispersed in the polymeric matrix material, each light generating microcapsule of the plurality of light generating microcapsules encapsulating multiple reactants that undergo a chemiluminescent reaction, wherein each light generating microcapsule comprises an outer shell and an inner shell,wherein the chemiluminescent reaction generates a photon having a wavelength within a particular emission range that is consistent with an absorption range of the photoinitiator and wherein the chemiluminescent reaction occurs without rupture of the outer shell of the light generating microcapsules.2. The self-healing polymeric material of claim 1 , wherein a crack in the polymeric matrix material causes migration of the monomers and photoinitiator into the crack.3. The self-healing polymeric material of claim 2 , wherein further propagation of the crack in the polymeric matrix material results in application of a compressive force to a light generating microcapsule of the plurality of light generating microcapsules claim 2 , the compressive force triggering the chemiluminescent reaction within the light generating microcapsule.4. The self-healing polymeric material of ...

Подробнее
Номер записи: 97
09-11-2017 дата публикации

Flash and Glow 1,2-Dioxetanes

Номер: US20170321245A1
Автор: Edwards Brooks, Mihali Albana, Wang Zhixian
Принадлежит:

Compounds having chemiluminescent flash and glow properties. Also disclosed are methods using the compounds to generate light, detect and/or quantify enzymes, antigens, and/or nucleic acids. Also disclosed are kits relating to these compounds. 193.-. (canceled)951. The compound of claim , wherein the cleavage of the bond cleavable by an enzyme moiety results in the generation of light at 37° C. which reaches a maximum in less than about 5 minutes.961. The compound of claim , wherein the cleavage of the bond cleavable by an enzyme moiety results in the generation of light at 37° C. which reaches a maximum in 3 minutes or less.100. A method for generating light , comprising the steps of:{'b': '1', '(a) providing a compound of claim ;'}(b) providing an enzyme complex comprising an enzyme moiety which is capable of cleaving the compound;(c) contacting the enzyme complex with the compound to form a reaction mixture; and,(d) allowing the reaction mixture to generate light.101. The method of claim 100 , wherein the cleavage of the bond cleavable by the enzyme moiety results in the generation of light at 37° C. which reaches a maximum in 3 minutes or less.105. The method of claim 100 , wherein the compound has a constant signal-to-noise ratio.106. The method of claim 100 , wherein the compound has improved sensitivity claim 100 , wherein sensitivity is defined as the lowest amount of hIL-6 detect at a signal-to-noise of 2.107. The method of claim 100 , wherein the enzyme moiety is a hydrolytic enzyme chosen from alkaline phosphatase claim 100 , β-galactosidase claim 100 , β-glucosidase claim 100 , β-glucuronidase claim 100 , or neuraminidase.108. A method for determining the presence and/or amount of an enzyme in a sample claim 100 , comprising the steps of:{'b': '1', '(a) providing a compound of claim ;'}(b) providing a sample suspected of comprising the enzyme which is capable of cleaving the compound so that it decomposes and generates light;(c) contacting the sample ...

Подробнее
Номер записи: 98
01-10-2020 дата публикации

POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT IN WHICH THE COMPOUND IS USED

Номер: US20200308488A1
Автор: Hayashi Masanao, Hosono Ayaki, Kadomoto Yutaka, Kai Hidetomo, Kusumoto Tetsuo, Miyamoto Masanori, Shimizu Kenta, Yamamoto Shinya
Принадлежит: DIC CORPORATION

The compound is represented by general formula (i). In the compound, in a group K, at least two secondary carbon atoms in an alkyl group (a linear alkyl, halogenated alkyl, or cyanogenated alkyl group having 3 to 40 carbon atoms) are replaced with —C(═X)— and/or —CH(—CN)—, where Xis an oxygen atom, a sulfur atom, NH, or NR; in addition, a group A, a group A, or the group Kincludes, as a substituent, at least one P-Sp- group, where Pis a polymerizable group, and SPis a spacer group or a single bond. The liquid crystal composition including the compound represented by general formula (i) can be adsorbed onto substrates between which a liquid crystal layer is held, and, consequently, without the use of an alignment film, liquid crystal molecules can be maintained in a state in which the liquid crystal molecules are aligned in a vertical direction. 3. The compound according to claim 1 , wherein{'sup': i1', 'i2', 'i3, 'A, A, and Ain general formula (i) represent a ring system selected from a 1,4-phenylene group, a 1,4-cyclohexylene group, a 1,4-cyclohexenylene group, an anthracene-2,6-diyl group, a phenanthrene-2,7-diyl group, a pyridine-2,5-diyl group, a pyrimidine-2,5-diyl group, a naphthalene-2,6-diyl group, an indan-2,5-diyl group, a 1,2,3,4-tetrahydronaphthalene-2,6-diyl group, and a 1,3-dioxane-2,5-diyl group, and'}{'sup': i1', 'i1', 'i2', 'i3', 'i1', 'i1', 'i1', 'i1, 'a hydrogen atom in Ais not replaced or is optionally replaced with L, and hydrogen atoms in Aand Aare not replaced or are optionally replaced with L, P-Sp-, or K.'}6. The compound according to claim 1 , wherein Rin general formula (i) represents an alkylene group having 3 or more carbon atoms claim 1 , and —CH— in the alkylene group is optionally replaced with —O— provided that oxygen atoms are not directly adjacent to each other.8. A liquid crystal composition comprising the compound represented by general formula (i) according to claim 1 , another polymerizable compound claim 1 , which is different ...

Подробнее
Номер записи: 99
08-10-2020 дата публикации

Stable amorphous eliglustat premix and process for the preparation thereof

Номер: US20200316025A1
Автор: Venkata Nookaraju Sreedharala, Vijaya Rajesh Kumar Yelchuri
Принадлежит: AIZANT DRUG RESEARCH SOLUTIONS PRIVATE Ltd

The present invention relates to pharmaceutical compositions of Eliglustat. In particular the present invention relates to stable amorphous Eliglustat premix having enhanced stability and dissolution properties. The present invention also provide a stable premix composition comprising amorphous Eliglustat or a pharmaceutical acceptable salt thereof, pharmaceutical compositions comprising the premixes, and processes for preparing the same. The compositions prepared in the present invention includes sublingual or mouth dissolving tablets, and capsules of Eliglustat and/or its pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable carrier.

Подробнее
Номер записи: 100